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ABSTRACT 
Under pathological conditions microglia (resident central nervous system (CNS) immune cells) 
become activated, and produce reactive oxygen and nitrogen species and pro-inflammatory 
cytokines: molecules that can contribute to disorders including stroke, traumatic brain injury, 
progressive neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, 
amyotrophic lateral sclerosis, multiple sclerosis, and several retinal diseases. Given that ATP is 
frequently released from CNS neurons during tissue damage and inflammation, its actions on 
microglia-mediated toxicity are especially pertinent. For example, the ATP-gated P2X7 purinergic 
receptor (P2X7R) cation channel is up-regulated around amyloid β-peptide plaques in transgenic 
mouse models of Alzheimer's disease and co-localizes to microglia and astrocytes. Upregulation of 
P2X7R on microglia occurs also following spinal cord injury and after brain ischemia. ATP, via 
activation of P2X7R, is one of the most powerful stimuli for secretion of the key pro-inflammatory 
cytokine interleukin-1β (IL-1β) in its mature form. This project investigates the pharmacological 
and biochemical behaviors of P2X7R on microglia and astrocytes cultured from rat cerebral cortex, 
spinal cord and cerebellum, and the relationship between these two glial cell types. 
 ATP is an efficient stimulus for IL-1β secretion only after the cells have undergone a short 
'priming' with endotoxin (lipopolysaccharide (LPS)). Indeed LPS, but not ATP caused release of IL-
1β from cortical microglia. However, it is known that the greater part of the IL-1β thus released is 
the precursor (biologically inactive) form. Purified (>99%) cortical microglia and enriched (≥95%) 
astrocytes were primed for 2 hours with LPS, followed by addition of ATP for 1 hour. Culture 
medium was then collected and the content of IL-1β quantified by ELISA. The effects of LPS and 
ATP were concentration-dependent; although LPS alone (but not ATP) modestly stimulated IL-1β 
release, levels of cytokine release were much higher from primed cells incubated with ATP. The 
ATP-dependent component was fully blocked by selective P2X7R antagonists, and followed their 
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known rank order of target potency. The P2X7R priming response was also seen with spinal cord 
and cerebellar microglia, a finding not described in the literature until now. 
To rule out a contribution by the minor population of microglia in our astrocyte cultures, the 
latter were treated with the lysosomotropic agent L-leucyl-L-leucine methyl ester (L-LME) which 
selectively eliminates cells with cytotoxic potential (e.g. macrophages, microglia). 
Immunocytochemical and molecular biological evaluation showed L-LME-treated cortical and 
spinal cord astrocytes to be fully depleted of microglia. These purified astrocytes failed to respond 
to LPS, and did not show the ATP priming behavior. Responsiveness was recovered upon addition 
of microglia to the L-LME-treated astrocytes and, moreover, a far more robust release of IL-1β 
occurred than that achieved with the same numbers of microglia alone. This astrocyte-microglia 
interaction was also observed for LPS-stimulated release of nitric oxide and IL-6, and was not 
mediated by astrocyte-derived soluble factors. 
Lastly, the LPS/ATP priming behavior was studied by examining the ability of other agents, 
linked to neuropathology, to replace either LPS or ATP. Neither ethanol (ethanol intoxication; in 
place of LPS) nor amyloid β-peptides (Alzheimer disease; in place of ATP) were able to provoke 
IL-1β release from microglia. However, both zymosan and poly(I:C), agonists of Toll-like receptors 
-2 and -3, respectively, were capable of substituting LPS (a Toll-like receptor 4 agonist) in the 
P2X7R priming response. Release of IL-1β in all these cases was antagonized by inhibitors of p38 
mitogen-activated protein kinase (a stress response kinase). 
TLRs contribute to CNS immunocompetent cell activation and the resulting pro-inflammatory 
cascade producing pathological pain. TLR4 recognizes not only LPS, but also ligands called 
damage associated molecular patterns, released by the injured tissue The involvement of 
extracellular TLR4 and TLR2, as well as TLR3 in preclinical pain models has been demonstrated. 
The findings described here further support the notion of astrocyte/microglia interaction, which may 
improve our understanding in how these cells respond to CNS injury or inflammation, in particular 
where TLRs are involved. 
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RIASSUNTO 
Le ricerche svolte hanno riguardato lo studio dei comportamenti della microglia e degli astrociti 
derivati da corteccia, midollo spinale e cervelletto di ratto in presenza di uno stimolo infiammatorio, 
in particolare quello associato alla famiglia dei recettori toll-like (TLR) e il recettore purinergico 
P2X7 (P2X7R).  E’ ormai riconosciuto il coinvolgimento della glia nello sviluppo delle malattie 
neurodegenerative e nel dolore neuropatico, sia nel midollo spinale che nelle aree corticali. In 
particolare, il rilascio di ATP da cellule danneggiate o morenti (cellule gliali, neuroni e cellule 
endoteliali) può agire come un segnale di 'pericolo' attraverso un sottotipo di recettori purinergici 
come il P2X7. I recettori P2X7 possono influenzare la morte cellulare attraverso la capacità di 
regolare il processo e il rilascio di interluchina-1β (IL-1β), un mediatore chiave nella 
neurodegenerazione, infiammazione e dolore cronico. L’IL-1β e' rilasciata dai macrofagi e dalla 
microglia esposta a endotossina batterica (lipopolisaccaride, LPS). Scopo della ricerca svolta è stato 
quindi la caratterizzazione di queste popolazioni di cellule gliali con metodi immunologici, 
molecolari, biochimici e farmacologici in presenza o assenza di stimolo infiammatorio (LPS)  e 
l'identificazione  del meccanismo del 'priming' (le cellule di microglia trattate per breve tempo con 
LPS diventano più sensibili all’azione dell’ATP) in termine di rilascio di IL-1β. Fino ad ora la 
maggior parte  degli studi presenti in letteratura hanno esaminato il ruolo della microglia ma non 
degli astrociti nella neuroinfiammazione. 
Il lavoro svolto nel primo anno è consistito principalmente nella caratterizzazione del 
comportamento della microglia e degli astrociti ottenuti da corteccia, midollo spinale e cervelletto, 
in termini di risposta ad ATP, in presenza o assenza di uno stimolo infiammatorio come LPS. Per 
questo scopo è stato utilizzato un modello in vitro di microglia preparata  da corteccia cerebrale di 
ratto di 1-2 giorni d’eta' o da midollo spinale. Dopo 1-2 settimane la popolazione di cellule di 
microglia vengono separate dagli astrociti e raccolte. Queste colture secondarie di microglia 
purificate (>99%) e astrociti arricchiti (>95%) (come determinato mediante colorazione 
immunocitochimica e l'espressione genica (RT-PCR), sono state trattate e il terreno di coltura è 
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stato utilizzato  per l’analisi (ELISA) delle citochine  (IL-1β, TNF-α, IL-6), rilasciate. Inoltre, nel 
terreno di coltura si è provveduto a valutare la quantità di ossido d’azoto (NO). La microglia e gli 
astrociti di controllo e trattati con ATP (fino a 5 mM) non producono una quantità misurabile di IL-
1β. Il LPS, alla dose di 100 ng/ml, produce invece un considerevole aumento di NO e IL-1β in 
funzione del tempo in tutte e due i tipi cellulari. 
Successivamente abbiamo analizzato la risposta della microglia e degli astrociti esposti per 
tempi brevi prima a LPS e poi ad ATP per stimolare il rilascio di una quantità maggiore di IL-1β 
matura ('priming'). Sia la microglia che gli astrociti, stimolati con LPS e ATP, rilasciano IL-1β . La 
parte della risposta data dall’ATP e non dall’LPS viene bloccata dagli antagonisti del P2X7R. L’ 
SB-202190, un inibitore selettivo della miogeno-activated-protein (MAP) chinasi p38, riduce il 
rilascio di IL-1β indotto da LPS nel 'priming', ma lo aumenta (da 6 a 10 volte) se incubato con LPS 
in presenza di siero per 24 ore. L’ SB-202190 inoltre, inibisce il rilascio di NO in cellule trattate con 
LPS per 24 ore. L’SP600125, un inibitore del c-Jun N-terminale chinasi (JNK), aumenta il rilascio 
di IL-1β indotto da LPS (24 ore) in microglia. In contrasto, nel priming l’SP600125 riduce il 
rilascio di IL-1β. I due meccanismi di rilascio  di IL-1β sono quindi presumibilmente diversi, ma 
legati alla cascata del segnale della MAP chinasi. La risposta 'priming' è stata anche dimostrata in 
microglia ottenuta da cervelletto di ratto. Questi resultati rappresentano la prima descrizione della 
risposta 'priming' nelle cellule gliali del midollo spinale e del cervelletto collegato al P2X7R. 
Il lavoro svolto nel secondo anno  è consistito principalmente nel caratterizzare dal punto di vista 
molecolare e farmacologico il rapporto tra microglia e astrociti in queste culture. Siccome le colture 
arricchite in astrociti contengono una piccola percentuale di microglia (<5%), abbiamo voluto 
verificare se il rilascio di citochine in seguito a uno stimolo infiammatorio dipende da una azione 
diretta sugli astrociti o una azione indiretta tramite la presenza della microglia. Per eliminare la 
microglia residua le colture arricchite in astrociti (corticali, spinali o cerebellari),  sono state trattate 
per un ora con l’agente lisosomotropico L-leucine methyl ester (L-LME) (50 mM), che è tossico per 
i macrofagi. Dopo un ora di incubazione la soluzione di  L-LME è stata sostituita da terreno di 
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coltura per 24 ore, al termine delle quali sono stati iniziati i trattamenti con lo stimolo 
infiammatorio. Da ora in poi definiamo tali colture come ‘astrociti purificati’. L’RNA messaggero 
(mRNA) per l’ Iba1, proteina espressa solo nella microglia, non è stato rilevato tramite la tecnica 
RT-PCR negli astrociti purificati, mentre il segnale è presente nelle cellule prima del trattamento 
con L-LME. Il trattamento con L-LME elimina anche la risposta LPS/ATP (priming)  negli astrociti 
corticali, spinali e cerebellari purificati. L’aggiunta di una quantità nota di microglia agli astrociti 
purificati, ripristina la risposta degli astrociti al priming. Tuttavia, lo stesso numero di microglia, da 
sola, senza la presenza degli astrociti, è insufficiente a produrre il segnale. Lo studio 
dell’interazione tra microglia e astrociti purificati, è stato esteso anche alla produzione dell’NO e 
mRNA per iNOS (NO sintasi inducibile). E’stato dimostrato che l’aumento della produzione di NO 
in seguito a stimolazione con LPS, è stata abolita negli astrociti purificati. L’aggiunta di una 
quantità nota di microglia alle cellule di astrociti purificati, ripristina la risposta degli astrociti al 
LPS e di conseguenza un aumento di iNOS e NO. Inoltre, il terreno di coltura dagli astrociti trattati 
con LPS non è grado a stimolare il rilascio di NO da microglia. Un comportamento simile è stato 
osservato per IL-6 mRNA e proteine. Questi dati mostrano chiaramente che la microglia, ma non gli 
astrociti rispondono al  LPS, e che il comportamento degli astrociti dipende dalla presenza di 
microglia. 
L'obiettivo ultimo era quello di esaminare, oltre al LPS o ATP,  la capacità di altri agenti 
potenzialmente patologici, ad esempio il peptide beta-amiloide (Aβ), l’etanolo, e agonisti del 
recettore TLR2 e TLR3 nella risposta 'priming' della microglia. Aβ, il  principale costituente delle 
placche che si trovano nel cervello dei pazienti affetti dalla malattia Alzheimer (AD), può attivare la 
microglia. E’ stato pubblicato che la proteina Aβ (25-35) aumenta la secrezione di IL-1β nella 
microglia esposta a LPS. Siccome nel cervello dei pazienti affetti da AD si accumula la forma (1-
42) della Aβ e non la (25-35),  tutte e due le forme sono state testate per vedere se sono in grado di 
sostituire l’ATP nella microglia pretrattata con LPS.  Nessuno dei due peptidi però si sono 
dimostrati efficaci. 
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L’ intossicazione da etanolo cronica e acuta promuove i processi infiammatori nel cervello e nelle 
cellule gliali agendo sul TLR4. L’etanolo, dunque, potrebbe attivare la microglia e sostituire LPS 
nella risposta 'priming' per l’ATP. Per dimostrare questa teoria, la microglia corticale e da midollo 
spinale è stata incubata con 100 mM etanolo o 1 µg/ml LPS per due ore, seguita da incubazione con 
5 mM ATP per un' ora. Successivamente è stato misurato il rilascio di IL-β nel mezzo di coltura che 
ha dimostrato l’effetto dell’ATP, ma non dell’etanolo, sulle cellule pretrattate con LPS.  
La microglia oltre al TLR4 esprime anche TLR2 e TLR3 funzionali che, quando attivati, 
partecipano al dolore neuropatico causato da lesioni nervose. Finora non sono stati fatti studi che 
dimostrano il coinvolgimento degli agonisti TLR2 e TLR3 sulla microglia ‘primed’ e il rilascio di 
citochina IL-1β. L’agonista TLR2 (Zymosan) e TLR3 (Poly(I:C)), sono stati dunque testati nella 
microglia al posto del LPS e si sono dimostrati capaci di attivare la microglia, corticale, spinale e 
cerebellare. In presenza di ATP sono stati in grado, come il LPS, di essere efficaci come ‘priming’ 
in termini di rilascio di IL-1β. Un inibitore selettivo della MAP chinasi p38 (SB-202190) riduce il 
rilascio di IL-1β indotto da Zymosan o Poly(I:C) nel 'priming', ma lo aumenta (circa 4 volte) se 
incubato per 24 ore, in presenza di siero. 
Questo studio costituisce un contributo originale alla ricerca nel campo della neuroinfiammazione a 
livello cellulare e in particolare il rapporto tra astrociti e microglia. Dato che gli astrociti sono molto 
più numerosi della microglia nel sistema nervoso centrale, questi dati suggeriscono che una simile 
interazione tra astrociti e microglia in vivo può essere un elemento importante per l'evoluzione di 
una patologia infiammatoria. Inoltre, questo lavoro dimostra per la prima volta che l'attivazione del 
P2X7R si verifica in microglia da midollo spinale e da cervelletto,  che può verificarsi con agonisti 
TL2 e TLR3 oltre che con TLR4. Questo amplia notevolmente le possibilità di partecipazione del 
recettore P2X7 nella neuroinfiammazione. 
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1. INTRODUCTION 
 
1.1. PURINERGIC NEUROTRANSMISSION AND SIGNALING - A HISTORICAL 
PERSPECTIVE 
 
It has been estimated that adenosine triphosphate (ATP) participates in more chemical reactions 
than any other molecule, except water. This is due, in no small measure to the evolutionarily 
progressive development of both complementary binding sites for ATP on cellular proteins, and 
various receptors for extracellular ATP on the plasma membrane of almost all cell phenotypes – in 
addition to the ancestral function of ATP as the main source of energy. Moreover, purine 
derivatives have been viewed as primordial precursors in the evolution of neurochemical 
transmission (Trams, 1981) – extracellular actions of ATP have been reported in very primitive 
organisms, including bacteria, diatoms, algae and slime moulds (Burnstock, 1996; Burnstock and 
Verkhratsky, 2009). Therefore, when examining the ontogeny and phylogeny of ATP functions and 
ATP receptors, one must keep in mind both short-term signalling, as typified by neurotransmission 
and secretion, and long-term signalling which involve not only cell proliferation, differentiation and 
death, but also plasticity of expression during pathological states.  
 The concept of purinergic neurotransmission was introduced in 1972 (Burnstock, 1972) after it 
was shown that ATP was a transmitter in non-adrenergic, noncholinergic inhibitory nerves in the 
guinea-pig taenia coli. Subsequently, ATP was identified as a co-transmitter in sympathetic and 
parasympathetic nerves (Burnstock, 1976), and it is now recognized that ATP acts as either sole 
transmitter or a cotransmitter in most nerves in both the peripheral nervous system and central 
nervous system (CNS) (Burnstock, 2007) (Table 1). 
Implicit in the concept of purinergic neurotransmission was the existence of postjunctional 
purinergic receptors, and the potent actions of extracellular ATP on many different cell types also 
implicated membrane receptors. Purinergic receptors were first defined in 1976 (Burnstock, 1976). 
Two years later a basis for distinguishing two types of purinoceptors, identified as P1 and P2 (for 
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adenosine and ATP/ADP, respectively), was proposed (Burnstock, 1978). At about the same time, 
two subtypes of the P1 (adenosine) receptor were recognised (Londos et al., 1980; Van Calker et 
al., 1979), but it was not until 1985 that a proposal suggesting a pharmacological basis for 
distinguishing two types of P2 receptors (P2X and P2Y) was made (Burnstock and Kennedy, 1985). 
In 1993, the first G protein-coupled P2 receptors were cloned (Lustig et al., 1993; Webb et al., 
1993), and a year later two ion-gated receptors were cloned (Brake et al., 1994; Valera et al., 1994). 
In 1994 Abbracchio and Burnstock (1994), on the basis of molecular structure and transduction 
mechanisms, proposed that purinoceptors should belong to two major families: a P2X family of 
ligand-gated ion channel receptors and a P2Y family of G protein-coupled receptors. This 
nomenclature has been widely adopted and currently seven P2X subtypes and eight P2Y receptor 
subtypes are recognized, including receptors that are sensitive to pyrimidines as well as purines 
(Abbracchio et al., 2006; North, 2002; Ralevic and Burnstock, 1998) (Table 2). 
 
----------------------------------------------------------------------------------------------------------------------------------- 
Table 1. ATP as a ubiquitous co-transmitter in peripheral and central nervous systems 
 
Neuron type      Co-transmitters 
 
Peripheral nervous system 
 
Sympathetic nerves      ATP + NA + NPY  
Parasympathetic nerves     ATP + ACh + VIP 
Sensory-motor       ATP + CGRP + SP 
NANC enteric nerves      ATP + NO + VIP 
Motor nerves (in early development)    ATP + Ach 
 
Central nervous system 
 
Cortex, caudate nucleus     ATP + ACh 
Hypothalamus, locus coeruleus     ATP + NA 
Hypothalamus, dorsal horn, retina    ATP + GABA 
Mesolimbic system      ATP + DA 
Hippocampus, dorsal horn, cortex    ATP + glutamate 
----------------------------------------------------------------------------------------------------------------------------------- 
ACh, acetylcholine; ATP, adenosine 5'-triphosphate; CGRP, calcitonin gene-related peptide; DA, dopamine; 
GABA, γ-aminobutyric acid; NA, noradrenaline; NANC, non-adrenergic, non-cholinergic; NO, nitric oxide; 
NPY, neuropeptide Y; SP, substance P; VIP, vasoactive intestinal polypeptide. 
(Compiled from Burnstock (2007)). 
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1.1.1. Storage, Release and Breakdown of ATP and Related Nucleotides 
 
The cytoplasm of most neurons contains ~2-5mM ATP, and higher concentrations of ATP (up 
to 100 mM) are stored in synaptic vesicles. Synaptic vesicles also contain other nucleotides such as 
adenosine diphosphate (ADP), adenosine monophosphate (AMP), diadenosine tetra- and 
pentaphosphate, and guanosine triphosphate, but at lower concentrations (Novak, 2003; Sperlágh 
and Vizi 1996). Accumulation of ATP into vesicles (Figure 1) can be mediated by a Cl--dependent 
vesicular nucleotide transporter, which belongs to the SLC17 anion transporter family, which 
includes also vesicular glutamate transporters (Sawada et al., 2008). This transporter is highly 
expressed in brain localized to chromaffin granules and subpopulations of astrocytes. ATP is 
probably present in every synaptic and/or secretory vesicle, although at different concentrations, 
and can be co-stored and co-released with other neurotransmitters (e.g. γ-aminobutyric acid, 
noradrenaline or glutamate; Table 1). 
At present, it is unclear whether various physiological nucleotide-receptor agonists (e.g. ATP, 
ADP, UTP, UDP, UDP sugars and NAD+) are released by common mechanisms. There is strong 
evidence for exocytotic neuronal vesicular release of ATP (Pankratov et al., 2007) (Figure 1); there 
is also support for vesicular release of ATP from astrocytes (Bowser and Khakh, 2007), which may 
involve lysosomes (Zhang et al., 2007). ATP released from nerves, or by autocrine and paracrine 
mechanisms from nonneuronal cells, is involved in a wide spectrum of physiological and 
pathophysiological activities, including synaptic transmission and modulation, pain and touch 
perception. 
After release, ATP and other nucleotides undergo rapid enzymatic degradation by 
ectonucleotidases, which is functionally important because ATP metabolites act as physiological 
ligands for various purinergic receptors (Figure 1). The ectonucleotidases not only control the 
lifetime of nucleotide ligands but, by degrading or interconverting the originally released ligands, 
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they also produce ligands for additional P2 receptors and nucleosides (Figure 1; Table 2) 
(Zimmermann, 2006). All ectonucleotidase families hitherto identified are expressed in the brain. 
These include the ectonucleoside triphosphate diphosphohydrolases, E-NPPs (ectonucleotide 
 
------------------------------------------------------------------------------------------------------------------------ 
Table 2 
 
History of P2X Receptor Pharmacology 
 
 
1929    Purines hypothesized as extracellular signaling molecules   
 
1930’s & 1940’s Effects of ATP and other nucleotides on tissues explored 
  
1950’s   ATP release from sensory nerves 
 
 1972   ATP proposed as a neurotransmitter 
 
1975   α,β- and β,γ-MeATP first used on gastrointestinal tissues 
 
P2      1978   "P2 purinoceptor" coined 
 
          1979   Reactive blue-2 first used as a P2 antagonist 
 
P2X/  1985   P2 receptors subclassified as P2X and P2Y 
P2Y   
 
1988                            Suramin identified as a P2 antagonist 
 
1989 BzATP activates P2Z (P2X7) 
 
1992    PPADS identified as a P2X antagonist 
 
1993      Oxidized ATP blocks P2Z (P2X7)  
 
P2X1-7      1994/1996    All seven P2X subtypes cloned  
 
 1998   TNP-ATP identified as selective antagonist of P2X1, 3, 2/3 
 
 
 2002   Selective small-molecule antagonists of P2X1,3, 2/3, 7 first identified 
 
   to 
 
present  Drug-like antagonists emerging; first clinical trials in man underway 
 
------------------------------------------------------------------------------------------------------------------------ 
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pyrophosphatase and/or phosphodiesterases), alkaline phosphatases and ecto-50-nucleotidase 
(Zimmermann, 2006). Individual enzymes differ in substrate specificity and product formation. 
Ectonucleoside triphosphate diphosphohydrolases and E-NPPs hydrolyze ATP and ADP to AMP, 
which is further hydrolyzed to adenosine by ecto-50-nucleotidase. Alkaline phosphatases equally 
hydrolyse nucleoside tri-, di- and mono-phosphates. Dinucleoside polyphosphates, NAD+ and UDP 
sugars are substrates solely for E-NPPs. Besides the catabolic pathways, nucleotide interconverting 
enzymes exist for nucleotide rephosphorylation and extracellular synthesis of ATP (e.g. 
ectonucleoside diphosphate kinase and adenylate kinase). Although usually adenosine is produced 
by ectoenzymatic breakdown of ATP, there might be subpopulations of neurons and/or astrocytes 
that release adenosine directly (Wall and Dale, 2007). 
 
Figure 1. Mechanisms of ATP release, degradation and reception 
 
 
Abbreviations: Alk Phos, alkaline phosphatase; Myok, myokinase (adenylate kinase); NDK, nucleoside 
diphosphate kinase; NPPs, nucleotide pyrophosphatase and/or phosphodiesterases; 50-Nuc, 50-nucleotidase; 
VNUT, vesicular nucleotide transporter. (Taken from Abbracchio et al., Trends Neurosci. 2009). 
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1.2. RECEPTORS FOR PURINES AND PYRIMIDINES 
 
1.2.1. P1 Purinergic Receptors 
 
The four adenosine receptors A1, A2A, A2B and A3 are G-protein coupled (Figure 1). Typically, 
A1 and A3 couple to the Gi/o family of G proteins inhibiting cyclic AMP (cAMP) production, 
whereas A2A and A2B stimulate cAMP production via Gs. Other G-protein combinations have been 
revealed as a function of cell type; however, all adenosine receptors activate at least one subfamily 
of mitogen-activated protein kinases (MAPKs) (Schulte and Fredholm, 2003). Accordingly, in the 
CNS, adenosine exerts a multitude of functions, including modulation of neural and glial functions, 
of neuron–glia signalling or of neural development (Daré et al., 2007; Fellin et al., 2006). 
Furthermore, adenosine plays an important part in the control of the innate and adaptive immune 
systems, and dysregulation of the adenosine system is involved in pathologies ranging from 
epilepsy to neurodegenerative disorders and psychiatric conditions (Boisen, 2008). 
 
1.2.2. P2Y Receptors 
 
The first G protein-coupled P2Y receptors were cloned in 1993 (Lustig et al., 1993; Webb et 
al., 1993), and there are currently eight accepted P2Y receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, 
P2Y12, P2Y13, and P2Y14. The missing numbers represent either non-mammalian orthologs or 
receptors that have some sequence homology to P2Y receptors but for which there is no functional 
evidence of responsiveness to nucleotides (Abbracchio et al., 2006). P2Y receptors are 308-377 
amino acid proteins with a mass of 41-53 kDa after glycosylation. The seven transmembrane (TM) 
domain tertiary structure of P2Y receptors is common to other G protein-coupled receptors (Figure 
1). P2Y are activated by purine or pyrimidine nucleotides or sugar-nucleotides with subtype-
dependent heterotrimeric G-proteins (Abbracchio et al., 2006). Site-directed mutagenesis studies 
have shown that some positively charged residues in TM3, 6 and 7 are crucial for receptor 
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activation by nucleotides (Jiang et al., 1997). Each P2Y receptor binds to a single heterotrimeric G 
protein (Gαq/11 for P2Y1, 2, 4, 6), although P2Y11 can couple to both Gαq/G11, and Gαs, whereas 
P2Y12 and P2Y13 couple to Gαi and P2Y14 couples to Gαi/Go (Abbracchio et al., 2006). In response 
to nucleotide activation, recombinant P2Y receptors either activate the phospholipase C-inositol 
trisphosphate pathway through Gαq/G11, which in turn releases intracellular calcium and activates 
protein kinase C, or affect adenylyl cyclase and alter cAMP levels through Gαi/Go (Abbracchio et 
al., 2006). Furthermore recent studies have shown that several P2Y receptors (P2Y2, P2Y6 and 
P2Y12) also coupled to Gα12/13, and nucleotide stimulation also activates Rho (Liao et al., 2007; 
Nishida et al., 2008) (Figure 2). 
P2Y receptors are expressed very early in the embryonic CNS and are broadly distributed on 
both neurons and glia. In contrast to P2X receptors (discussed below), P2Y receptors are activated 
not only by ATP but also by its metabolite ADP, uracil nucleotides (UTP, UDP), sugar nucleotides, 
or both adenine and uracil nucleotides (i.e. P2Y2) (Abbracchio et al., 2006). For P2Y1 receptors, 
ADP is a more potent agonist than ATP (their 2-methylthio derivatives are even more potent). The 
most effective antagonists to display selectivity for the P2Y1 receptor are MRS2179 (Boyer et al., 
1998), MRS2279 (Boyer et al., 2002) and MRS2500 (Kim et al., 2003). P2Y2 receptors are fully 
activated by equivalent concentrations of ATP and UTP, whereas ADP and UDP are much less 
effective agonists. P2Y6 receptors are selective for UDP (Abbracchio et al., 2006). A 1,4- di-
(phenylthioureido) butane derivative (MRS2578) (Mamedova et al., 2004) has been shown to 
selectively inhibit UDP-induced phospholipase C activity through P2Y6 receptors. P2Y12 receptors 
are also activated selectively by ADP and blocked by the 5′-triphosphate derivative AR-C69931MX 
(Ingall et al., 1999) (although this antagonist also blocks P2Y11 and P2Y13 receptors (Abbracchio et 
al., 2006; Communi et al., 1999)). The active metabolite of the antiplatelet drug clopidogrel is a 
potent and selective antagonist of P2Y12 receptors (Savi and Herbert, 2005). 
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Figure 2. Schematic representation of P2Y receptor signaling 
 
 
P2Y receptors can be divided into two principal subtypes (a and b) as a function of their G-protein 
coupling. DAG, diacylglycerol; IP3, inositol trisphosphate; PIP2, phosphatidylinositol 4,5-
bisphosphate; PKA, protein kinase A; PKC, protein kinase C.PLC, phospholipase C.   
 
 
 
P2Y receptors might generate homodimers or heterodimers with other P2Y receptors (Ecke et 
al., 2008) or with other transmitter receptors (e.g. A1 adenosine receptors (Fischer and Krügel, 
2007). Interactive molecular pathways include: nucleotide-induced transactivation of tyrosine 
kinase receptors (such as epidermal growth factor receptor, platelet-derived growth factor receptor 
and vascular endothelial growth factor receptor-2); activation of soluble tyrosine kinases (such as 
Src, or of ectometalloproteases (Camden et al., 2005)); and interaction with integrins or the nerve 
growth factor receptor and their signalling pathways (Arthur et al., 2005; Erb et al., 2006; 
Milenkovic et al., 2003; Neary and Zhu, 1994). 
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1.2.3. P2X Receptors 
 
P2X receptors are classical cationic ligand-operated channels that upon ATP binding open the 
pore permeable to Na+, K+, and Ca2+ (Figure 1). The P2X receptors are trimers (Nicke et al., 1998) 
formed from individual subunits encoded by seven distinct genes (designated P2X1 to P2X7 
according to historical order of cloning (North, 2002; Roberts et al., 2006)). Diversity of the P2X 
receptor phenotypes is determined by assembly of individual subunits; hitherto six homomeric 
(P2X1-P2X5 and P2X7; P2X6 subunits apparently do not oligomerize (Nicke et al., 1998)) and six 
heteromeric (P2X1/2, P2X1/4, PX1/5, P2X2/3, P2X2/6, and P2X4/6) channels have been identified 
(Roberts et al., 2006). Homomeric P2X7 receptors (P2X7R) are activated at 100-1000 μM ATP 
concentrations and the rest of receptors have an EC50 of ~1-10 µM. All P2X subunits are expressed 
in neural cells; this expression is heterogeneous in different brain regions and cell types. In many 
central neurons, expression is mosaic (and far from being fully characterised), which determines 
exceptional variability of ATP-induced current responses (Pankratov et al., 2003). Peripheral 
neurons (both sensory and autonomic) predominantly express P2X3 and P2X2/3 receptors, which are 
implicated in pain and temperature perception. The homomeric P2X3 channels have a unique 
temperature sensitivity (Khmyz et al., 2008); their rate of desensitisation is temperature insensitive, 
whereas the recovery from desensitization shows exceptional temperature dependence (temperature 
coefficient, Q10 ~10).  
All P2X receptors are permeable to Ca2+; the ratio of Ca2+ to monovalent cations permeability 
varies between 1 and >5-10 for various P2X subunit combinations (Egan et al., 2006; Pankratov et 
al., 2009). Native ATP-induced currents in several types of central neurons, such as neurons from 
medial habenula and somatosensory cortex, have an exceptionally high Ca2+ permeability 
(PCa:Pmonovalent = ~10-12 (Edwards et al., 1997; Pankratov et al., 2002)), which is comparable to the 
Ca2+ permeability of N-methyl-D-aspartate (NMDA) receptors. As a result, P2X receptors might 
provide the most important route for Ca2+ influx at the postsynaptic density at resting membrane 
potentials when NMDA receptors are unavailable owing to Mg2+ block (Pankratov et al., 2003). 
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Indeed, stimulation of P2X receptors triggers cytosolic Ca2+ signals in many CNS neurons 
(Pankratov et al., 2009), and P2X-mediated presynaptic Ca2+ signals can regulate neurotransmitter 
release (Sperlágh et al., 2007). The involvement of the P2X7R pore in apoptosis induction via 
sustained entry of Ca2+ into cells is discussed later. 
Postsynaptic P2X receptors interact with several ionotropic receptors including nicotinic 
acetylcholine receptors, GABAA receptors and NMDA receptors; for all these a reciprocal 
inhibition was demonstrated. The mechanisms for these interactions might be mediated by 
intracellular Ca2+, by Ca2+-activated kinases phosphorylating the receptors, or by direct interactions 
between receptors molecules (Khakh et al., 2000; Pankratov et al., 2008). 
 
1.2.4. P2X7 receptors 
 
Keller in 1966 was the first to discover that DNA synthesis and cytotoxicity in human and rat 
lymphocytes and mast cells required high concentrations (100 µM) of extracellular ATP, and was 
furthermore a receptor-mediated process (Keller, 1966). In 1979, Cockcroft and Gomperts 
recognized that some of the biological effects induced by extracellular ATP in rat mast cells, above 
all permeability to metabolites and nucleotides, degranulation and histamine release, also required 
very high concentrations of ATP, selectively binding to a receptor in the form of  ATP4- (Cockcroft 
and Gomperts, 1979). These pore-forming, high extracellular ATP receptors were also found in 
transformed rat fibroblasts (Heppel et al., 1985; Rozengurt and Heppel, 1979). Gordon (1986) later 
classified all these activities as mediated by a receptor defined as P2Z. Pore-forming P2Z receptors 
were subsequently demonstrated to play an important role in ATP-mediated plasma membrane 
permeability and cytotoxicity of mouse lymphocytes (Di Virgilio et al., 1989), and in the 
modulation of macrophage functions (el-Moatassim and Dubyak, 1992). 
Surprenant et al. (1996) subsequently published the cDNA sequence of the rat P2X7R gene, 
identified as the cytolytic P2Z receptor for extracellular ATP. The following year, Rassendren et al. 
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(1997) cloned the human gene for a receptor, called P2X7R that was structurally related to the P2X 
family and exhibited most of the properties of a P2Z receptor. They screened a human monocyte 
cDNA library with the rat P2X7R gene as a probe, and recovered a cDNA encoding a predicted 
595-amino acid protein that was 80% identical to the rat P2X7R protein. P2X7R is expressed as a 6-
kb mRNA in many tissues. Buell et al. (1998) determined that the P2X7R gene contains 13 exons, is 
localized close to the tip of the long arm of human chromosome 12(q24.31) and is <24 kb pairs 
apart from the P2X4R gene and presumably reflects gene duplication, given that P2X4R and P2X7R 
subunits are among the most closely related P2X receptor pairs in amino acid sequences (with 
48.6% pairwise amino acid identity). Box 1 presents an ‘identity card’ for the P2X7R. 
 
1.2.4.1. Biologically significant coding sequence variants  
 
Genetic variability is important for biodiversity and underlies the differential resistance of 
organisms to diseases and their sensitivity to toxic agents and conditions, or drugs. Without 
variability, mediated for instance by homologous recombination or genetic mutations, a population, 
a gene, or a protein adapts poorly to environmental changes and becomes more prone to extinction. 
ATP appears to have played a crucial and active role since early evolution, and the progressive 
generation of a wide range of ATP receptors mediating its extracellular actions has certainly 
contributed to expand and consolidate ATP functions, while at the same time increasing the 
potential genetic variability of ATP receptors. Box 2 summarizes the taxonomic relationships of 
P2X7R expression. 
Regarding P2X7R subtypes, in some healthy subjects the receptor appears to be non-functional 
in, for example, lymphocytes and monocytes. To study a possible genetic basis for this, in a 
population study Gu et al. (2001) sequenced the DNA coding for the carboxyl-terminal tail of the 
P2X7R protein. Unresponsive subjects were characterized by a 1513A-C substitution, which 
resulted in a glu496-to-ala (E496A) mutation. Monocytes and lymphocytes from E496A 
homozygote subjects expressed non-functional receptors, whereas heterozygotes showed P2X7R 
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BOX 1 
 
P2X7R ID chart 
 
Chromosomal location: 12(q24.31) in human, chromosome 12 in chimpanzee, 26 in dog, 17 in cow, 14(q14) in pig, 
5(62.5cM) in mouse, 12(q16) in rat, 15 in chicken, 8 in zebrafish. 
 
Gene structure: 13 exons (Buell et al., 1998) and multiple splice variants (Cheewatrakoolpong et al., 2005). 
 
Protein properties:  
• molecular mass: 85, 65, and 18 KDa. The 65-KDa P2X7R, the most common isoform, is a mature receptor, 
whereas the 85-KDa protein is a naïve receptor, and the 18-kDa protein is the degraded form. Receptor 
maturation likely involves glycosylation events, with substantial differences in glycosylation between human 
and other species (Feng et al., 2005). 
• average isoelectric point: 8.008, according to DTASelect, EMBOSS, Grimsley, Lehninger, Rodwell, Sillero, 
Solomon, ProMoST scales; 8.085, as determined by net charge values available from Lehninger's scale.  
 
Post-translational modifications: 
• phosphorylation: phosphotyrosine at residue 343 results in receptor inactivation (Kim et al., 2001); 
• ADP-ribosylation: ADP-ribosylarginine at Arg-125, but not Arg-133, is necessary and sufficient to activate 
P2X7R and gate the channel (Hong et al., 2009; Seman et al., 2003). 
• N-linked glycosylation, at residue 187, 202, 213, 241, 284: N-linked acetyl-glucosamine sites are important for 
receptor function and essential for trafficking to the cell surface (Lenertz et al., 2010). 
 
Interactants: 
• ABL1 (Abelson tyrosine-protein kinase 1): non-receptor tyrosine-protein kinase playing a role in cytoskeleton 
remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, 
DNA damage response and apoptosis (Wu et al., 2007). 
• GRB2 (growth factor receptor-bound protein 2): adapter protein providing a link between cell surface growth 
factor receptors and Ras signaling pathway (Wu et al., 2007). 
• NCK1 (non-catalytic region of tyrosine kinase 1): signalling and transforming cytoplasm protein containing 
Src homology 2 and 3 domains and involved in transducing signals from receptor tyrosine kinases to 
downstream recipients such as Ras (Wu et al., 2007). 
• EMP3 (hematopoietic neural membrane protein): involved in cell proliferation, cell-cell interactions (Wu et 
al., 2007). 
• PANX1 (pannexin 1): structural component of gap junctions and hemichannels, playing a role as a Ca2+-leak 
channel to regulate endoplasmic reticulum Ca2+ homeostasis (Iglesias et al., 2008).  
• LAMA3 (extracellular matrix protein laminin alpha3), ITGB2 (membrane-spanning protein integrin subunit 
beta-2), ACTB (cytoskeletal beta-actin), ACTN4 (cytoskeletal alpha-actinin 4), SVIL (cytoskeletal 
supervillin), MAGuK (scaffolding protein membrane-associated guanylate kinase P55), heat shock proteins 
Hsp90, Hsc71 and Hsp70, PIK230 (phosphatidylinositol 4-kinase 230) and PTPRB (membrane-spanning 
receptor protein tyrosine phosphatase beta) (Kim et al., 2001).  
 
Cellular components: bleb, cytoplasm, integral to plasma membrane (Morelli et al., 2003), nuclear envelope (Atkinson 
et al., 2002). 
 
                           (Modified from Volontè et al. CNS Neurol Disord Drug Targets 2012) 
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BOX 2 
 
P2X7R taxonomic groups 
 
● VERTEBRATES 
○ MAMMALS 
 Primates Hominidae:  
 Homo: Homo sapiens (human) 595 aa 
 Pan: Pan troglodytes (chimpanzee) 595 aa 
 Rodents 
  Muridae 
  Mus: Mus musculus (mouse) 595 aa 
  Rattus: Rattus norvegicus (rat) 595 aa 
  Meriones: Meriones unguiculatus (mongolian gerbil) 126 aa 
  Caviidae: Cavia porcellus (guinea pig) 594 aa 
  Carnivores: Canis lupus familiaris (dog) 595 aa 
  Even-toed ungulates 
  Suidae: Sus scrofa (pig) 318 aa 
  Bovidae: Bos taurus (cattle) 168 aa 
  Rabbits & hares: Oryctolagus cuniculus (rabbit) 595 aa 
○ AMPHIBIANS: Xenopus Laevis (frog) 553 aa 
○ BONY FISHES 
  Cypriniformes: Danio rerio (zebrafish) 596 aa 
  Perciformes:  Sparus aurata (silver seabream) 576 aa 
○ AVES:  Gallus gallus (chicken) 560 aa 
 
Cloned and conserved in: human (Rassendren et al., 1997), chimpanzee, dog (Roman et al., 2009), cow 
(Zimin et al., 2009), mouse (Chessell et al., 1998b), rat (Surprenant et al., 1996), chicken and zebrafish 
(Kucenas et al., 2003). Also cloned in Xenopus laevis (only 50% homology to the mammalian receptor) 
(Paukert et al., 2002), guinea pig (70% homology to the rat receptor) (Fonfria et al., 2008), gerbil, pig, 
rabbit, and silver seabream (unpublished).There are no reports of homologous sequences from invertebrate 
species, although there is considerable functional evidence that extracellular ATP and other nucleotides can 
directly gate ion channels in invertebrates. 
                                                       
                              (Modified from Volontè et al. CNS Neurol Disord Drug Targets 2012) 
 
function that was half that of germline P2X7R. P2X7R-mediated apoptosis of lymphocytes was 
impaired in homozygous mutant P2X7R protein compared with germline, while surface expression 
of P2X7R on lymphocytes was not affected by this E496A polymorphism. Single nucleotide splice 
site polymorphism at position +1 in intron 1, SNP 151+1g>t, led to a null allele of the P2X7R gene 
in 1-2% of the Caucasian population (Skarratt et al., 2005). As further examples, Adriouch et al. 
(2002) demonstrated that splenic T cells from C57BL/6 mice were less sensitive to extracellular 
ATP-induced calcium uptake and apoptosis than were those from BALB/c mice. The authors 
identified a single nucleotide allelic mutation, a T-to-C transition at nucleotide 1352, leading to a 
 26 
pro451-to-leu (P451L) substitution in the long cytoplasmic COOH tail of the P2X7R, which 
harbors a putative tumor necrosis factor receptor-related death domain. By transfecting Xenopus 
oocytes with either wild-type or site-directed mutants of P2X7R protein, Worthington et al. (2002) 
highlighted the importance of various residues in ATP binding to human P2X7R, finding that point 
mutation of residues K193 and K311 confers loss-of-function in terms of channel/pore activity. The 
variant lacking the entire C-terminal cytoplasmic tail is generally highly expressed in human tissues 
and does not effect ion movement; rather, it severely affects the ability to form a large pore and to 
induce activation for instance of caspases (Cheewatrakoolpong et al., 2005). The variant lacking the 
first transmembrane domain is also highly expressed in various human tissues and results in 
impaired channel activity (Cheewatrakoolpong et al., 2005). Conversely, the P2X7R splice variant 
with an alternative intracellular N terminus and first transmembrane domain encoded by a novel 
exon 1 in the rodent P2X7R gene, has increased agonist sensitivity and higher propensity to form N-
methyl-D-glucamine permeable pores (Nicke et al., 2009). The tissue and cellular distribution of 
P2X7R in human, rat and mouse is given in Box 3. 
 
1.2.4.2. Ion permeability and current properties 
 
Highly selective for the ATP4- species, stimulation of P2X7R with high concentrations of ATP 
triggers massive trans-membrane, poorly selective, ion fluxes (particularly influx of Ca2+ and Na+, 
and efflux of K+) and, at lower concentrations, slowly inactivating cation currents, thus exhibiting 
complex gating kinetics. The ability of P2X7R to act as a direct conduit for Ca2+-influx, and indirect 
activator of voltage-gated Ca2+-channel underlies its multiple role in Ca2+-based signalling 
responses. In addition, P2X7R channel opening gives rise to Ca2+-independent anion currents, while 
addition of excess Mg2+ closes the receptor channel (Wiley et al., 1996). Extracellular ATP through 
P2X7R also induces equal efflux and influx of Rb+ (in isotonic KCl medium) and of Na+ (in 
isotonic NaCl medium) (Sluyter et al., 2004). P2X7R also elicits chloride conductance I (ATPCl)  
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BOX 3 
 
P2X7R tissue and cell distribution 
 
Human: 
• high in heart, liver, skeletal muscle, pancreas, thymus, tonsils, monocytes, macrophages, osteoclasts 
(Buell et al., 1998; Gartland et al., 2003; Rassendren et al., 1997);  
• medium in brain, lung, prostate, leukocytes, fibroblasts, dendritic cells, osteoblasts, B lymphocytes, 
T lymphocytes, keratinocytes, erithrocytes, microglia (Amadio et al., 2010, 2011; Berchtold et al., 
1999; Buell et al., 1998; Gartland et al., 2003; Greig et al., 2003; Rassendren et al., 1997; Sluyter et 
al., 2001, 2004; Solini et al., 1999; Yiangou et al., 2006; Yip et al., 2009); 
• low in bladder, astrocytes (Narcisse et al., 2005; O'Reilly et al., 2001). 
 
Rat: 
• high in newborn and adult brain, bone marrow, retina, salivary glands, parotid gland, lacrimal 
glands, lung, spleen, pancreas, liver, testis, ependyma, neurons from olfactory nucleus, cerebral 
cortex, striatum, piriform cortex, lateral septal nucleus, hippocampal pyramidal cells, 
oligodendrocytes, microglia, macrophages, osteoclasts (Brändle et al., 1998; Cavaliere et al., 2004; 
Collo et al., 1997; Coutinho-Silva et al., 2003; Emmett et al., 2008; Franke et al., 2004; Frizzo et 
al., 2010; Hodges et al., 2009; Melani et al., 2006; Naemesch et al., 2001; Sugiyama et al., 2010; 
Tenneti et al., 1998; Yu et al., 2008).  
 
Mouse: 
• high in bone marrow, submandibular glands, lung, liver, kidney, macrophages, granulocytes, B 
lymphocytes, mast cells, microglia, Schwann cells, osteoclasts, osteoblasts (Chessell et al., 1998b; 
Collo et al., 1997; Colomar et al., 2001; D'Ambrosi  et al., 2009; Emmett et al., 2008; Ferrari et al., 
1997a; Grol et al., 2009; Hillman et al., 2002; Ke et al., 2003; Sim et al., 2004). 
                    
                         (Modified from Volontè et al. CNS Neurol Disord Drug Targets 2012) 
 
when a Ca2+-independent Cl- channel is gated in the P2X7R directly by external ATP (Reyes et al., 
2008). In Na+-free solutions, chloride conductance I (ATPCl) of P2X7R has an apparent anion 
permeability sequence of SCN- > I- > NO3- > Br- > Cl- > acetate (Arreola and Melvin, 2003). The 
P2X7R is activated and deactivated monophasically at low and biphasically at higher agonist 
concentrations. The binding of orthosteric agonists at the ectodomain moreover induces a 
conformational change in the receptor complex that favours a gating transition from closed, to open, 
to dilated states. The slow secondary growth of current in the biphasic response coincides 
temporally with pore dilation. Once a steady level of the secondary current is reached, responses at 
high agonist concentrations are no longer biphasic but monophasic. Repetitive stimulation with the 
same agonist concentration causes receptor sensitization, which manifests as a progressive increase 
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in current amplitude, accompanied by slower deactivation rate. Sensitization of the receptor is 
independent of Na+ and Ca2+ influx and about 30 minutes of washout is needed to re-establish the 
initial gating properties. Thus, the complex pattern of gating exhibited by P2X7R channels includes 
negative cooperativity of agonist binding to unsensitized receptors (caused by occupancy of one or 
two binding sites), opening of the channel pore to a low conductance state (when two sites are 
bound), and sensitization with pore dilation to a high conductance state (when three sites are 
occupied) (Yan et al., 2010). Figure 3 illustrates the structure and functioning of the P2X7R. Table 
1 summarizes the pharmacology of P2X7R. 
 
1.2.4.3. Topology and structure  
 
Understanding receptor structure-function, in this case P2X7R, depends not only on the exact 
"shape" of the receptor itself, but rather on the way the receptor is "assembled". In essence, a 
problem of continuity (topology) and connectivity (biology), in other words the properties that are 
preserved under continuous deformations of objects, and namely the stretching of a receptor on a 
differently fluid plasma membrane, its conformational twisting after ligand binding, and the layout 
pattern of interconnections with various elements: the basic characteristics of P2X7R. 
In 1997, Hansen et al. (1997) studied the topology of P2X7R on the plasma membrane, 
establishing that amino acids N-1-25 reside on the cytoplasmic side; amino acids 26-46 constitute 
the highly hydrophobic transmembrane TM1 region; amino acids 47-334 are responsible for the 
extracellular loop; amino acids 335-355 form the transmembrane TM2 region; amino acids 356-
595-C are present on the cytoplasmic side. The N terminus has residues related to selectivity and 
activity of the ion channel and interaction with mitogen-activated protein kinases (Amstrup and 
Novak, 2003). Only one α-helix is predicted in the TM1 segment, and a major propensity for β-
sheet conformation is expected in the TM2 region (Teixeira et al., 2009). Some residues of the
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Figure 3. Structure and function of the P2X7R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) Each functional P2X7R is a trimer, with the three protein subunits arranged around a cation-
permeable channel pore. The subunits all share a common topology, possessing two plasma 
membrane spanning domains (TM1 and TM2), a large extracellular loop with the ATP binding site, 
and containing 10 similarly spaced cysteines and glycosylation sites, and intracellular carboxyl and 
amino termini. (b) Brief ATP activation (<10 seconds) of the P2X7R results in rapid and reversible 
channel opening that is permeable to Na+, K+, and Ca2+. Acute receptor activation also triggers a 
series of cellular responses, such as depolarization, degranulation, and membrane blebbing, along 
with signaling cascades (see Figure 3). (c) Continued stimulation results in the formation of a larger 
plasma membrane pore, which facilitates the uptake of cationic molecules up to 900 Da. ATP-
induced IL-1β release is mediated mainly through the activation of IL-1β converting enzyme (also 
known as caspase-1). Activation of P2X7R triggers the efflux of K+ from cells which in turn 
activates IL-1 converting enzyme, leading to cleavage of pro-IL-1β to mature IL-1β and release 
from the cell. 
(Taken from Skaper et al. FASEB J. 2010)
Apoptosis
Lysis
IL-1β release
Degranulation
Membrane blebbing
IL-1β release
K+
PLD activation
ATP efflux
Caspase activation
Na+
Ca2+
ATP
NH+3 COO-
Depolarization
(brief)
Depolarization
(sustained)
ATP
TM1 TM2
(A) (B) (C)
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Table 1. P2X7R Pharmacology 
 
Compound Pharmacological 
Characteristics 
Biological 
Action(s) 
Reference(s) 
Agonists 
 
   
BzATP (3'-O-(4-
benzoyl)benzoyl-ATP) 
EC50 = 35-617 µM  Donnelly-Roberts et 
al. (2004) 
    
Antagonists (updated to June 2012 
from www.clinicaltrial.gov) 
 
   
GSK1482160 (Phase I) for inflammatory pain  Arulkumaran et al. 
(2011); Ali et al. 
(2012) 
AZD9056 (Phase II) for rheumatoid 
arthritis 
 Arulkumaran et al. 
(2011); Keystone et 
al. (2011) 
CE-224,535 (Phase III) for rheumatoid 
arthritis 
 Arulkumaran et al. 
(2011); Stock et al. 
(2012) 
    
Antagonists (preclinical phase) 
 
   
A438079 Competitive antagonist (pIC50 
= 6.9 for inhibiting Ca2+ influx 
in human recombinant P2X7R 
cells) 
Antinociceptive 
role in neuropathic 
pain in vivo 
models 
Donnelly-Roberts et 
al. (2007); 
McGaraughty et al. 
(2007) 
A740003 Potent, selective and 
competitive antagonist (IC50 
values of 18 and 40 nM for rat 
and human receptor, 
repectively) 
Antinociceptive in 
neuropathic pain 
and inflammatory 
animal models 
Donnelly-Roberts et 
al. (2009) 
A839977 Potent antagonist of BzATP-
evoked calcium influx at 
recombinant human, rat, mouse 
receptors (IC50 = 20, 42, 150 
nM, respectively) 
Antinociceptive in 
inflammatory pain, 
rat, mouse models, 
CNS permeant 
Honore et al. 
(2009); Friedle et 
al. (2010) 
AZ-1060620 Potent antagonist and negative 
allosteric modulator (KD = 1.4 
and 19 nM at human and rat 
receptor, respectively). It 
cooperatively binds to sites 
distinct but coupled to the ATP 
binding sites  
 Michel et al. (2008) 
AZ-11645373 Potent selective antagonist (KB 
= 5-7 and > 10,000 nM at 
human and rat, respectively). It 
inhibits BzATP-calcium influx 
, ATP- IL-1β release in vitro 
(KB =15 and 92 nM at human 
and rat, respectively) 
 Michel et al. (2009) 
Oxidized ATP Irreversible inhibitor, covalent 
modification of receptor (IC50 
= 30 μM) 
 Murgia et al. (1993) 
KN-62 Non-competitive antagonist 
(IC50=15 nM). Selective, cell-
permeable inhibitor of CaM 
kinase II (IC50 = 0.9 μM) 
 Chessell et al. 
(1998a) 
31 
Brilliant Blue G Non-selective antagonist (IC50 
=10 nM and 267 nM at rat and 
human receptor, respectively) 
Protects cortical 
neurons from 
BzATP-activated 
microglia 
Friedle et al. 
(2010); Skaper et 
al. (2006); 
Gunosewoyo et al. 
(2007); Takenouchi 
et al. (2010)  
 
    
Modulators 
 
   
Calcium At physiological concentrations 
acts as negative allosteric 
modulator by decreasing the 
affinity for orthosteric agonists 
 Yan et al. (2011)  
Zinc, Copper Potent inhibitors at 
submicromolar ranges, due to 
interaction with ectodomain 
His(62) and Asp(197) 
 Liu et al. (2008)  
Extracellular acidification Functional inhibition by acidic 
pH is potently affected by the 
extracellular His(85), Lys(110), 
Lys(137), Asp(197), His(219) 
residues, with Asp(197) residue 
being the most critical one 
 Liu et al. (2009) 
Extracellular anions Chloride, iodide, nitrate, sulfate 
inhibit ATP-induced human 
P2X7R-mediated currents, 
allosterically affecting channel 
opening in fully ATP4--
liganded P2X7R, through 
extracellular anion binding site 
 Kubick et al. (2011) 
Compound-17: 
 (N-[2-({2-[(2hydroxyethyl)amino] 
ethyl}amino)-5-quinolinyl]-2-tricyclo 
[3.3.1.1(3,7)]dec-1-ylacetamide) 
Negative allosteric modulator 
of human and rat P2X7R 
 Michel et al. (2008) 
GW791343:  
(N (2)-(3,4-difluorophenyl)-N (1)-[2-
methyl-5-(1-piperazinylmethyl) 
phenyl]glycinamidedihydrochloride) 
Negative allosteric modulator 
of human P2X7R  (pIC50=6.9-
7.2), but positive allosteric 
modulator at rat P2X7R 
 Michel et al. (2008) 
PIP2 Activator of ATP-gated 
currents, mutations of charged 
residues in C-terminus of 
P2X7R reduces the apparent 
affinity for PIP(2) and ATP-
mediated cell death 
 Zhao et al. (2007) 
Decavanadate Reversible, competitive 
antagonist (against pyridoxal 5-
phosphate, oxidised ATP, but 
not KN62) 
 Michel et al. (2006) 
Propofol Intravenous anesthetic, 
increases P2X7R current 
amplitudes and inactivation 
times  
 Liu et al. (2012) 
Clemastine (H1 antihistaminic) Positive allosteric modulator   Nörenberg et al. 
(2011) 
 
               (Adapted from Volontè et al. CNS Neurol Disord Drug Targets 2012) 
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extracellular loop displaying three different binding sites for ATP are glycosylated in the ATP-
interacting sequence. The intracellular COOH terminus (239 amino acids) is much longer than in all 
other P2XR subtypes, and is involved in the majority of functions related to P2X7R and contains an 
additional hydrophobic domain (residues 510–530) sufficiently long to traverse the plasma 
membrane (Costa-Junior et al., 2011). 
 Substantial evidence supports a trimeric structure for P2X7R, although scattered evidence 
suggests that it might aggregate to form examers (Kim et al., 2001b). It has been suggested that it 
forms heteromers with P2X4R (Casas-Pruneda et al., 2009; Dubyak, 2007; Guo et al., 2007). 
However, in another study using subtype-specific antibodies in combination with blue native 
polyacrylamide gel electrophoresis to directly visualize P2X receptor complexes solubilized from 
membrane extracts of a wide variety of tissues, homotrimeric complexes were the dominant 
assembly state of P2X7R complexes (Nicke, 2008). No complexes corresponding to more than three 
subunits or heterotrimeric P2X4R/P2X7R were detected, suggesting that either higher 
heteromerization between P2X4R and P2X7R subunits results in unstable heteromeric complexes, 
or that such P2X4R/P2X7R heteromers do not represent a dominant subtype in the tissues 
investigated (Nicke, 2008). However, a variety of proteins interacting with the P2X7R have been 
identified by immunoprecipitation of P2X7R over-expressed in HEK cells (Kim et al., 2001a) and, 
moreover, in a yeast two-hybrid screen (Wilson et al., 2002). Transient interaction via one of these 
proteins could also account for these copurification results (Guo et al., 2007). The potential 
contribution of recently identified splice variants of the human P2X7R (Cheewatrakoolpong et al., 
2005) to subunit assembly represents another element for consideration. Further studies will be 
needed to resolve this issue. 
In contrast to other P2X receptors, but in certain aspects similar to the activation profile found 
in some cells expressing P2X2R and P2X4R, stimulation of the P2X7R subtype with high 
concentrations of ATP is associated with two different membrane permeability states: a small non-
selective monovalent and divalent cation conductance which opens within milliseconds after brief 
33 
agonist stimulation, leading to depolarization of the plasma membrane (North, 2002), followed by 
increased non-selective membrane permeability to larger cations such as N-methyl-D-glucamine 
(molecular weight 195) after prolonged and repetitive agonist stimulation (Rassendren et al., 1997). 
Membrane permeability increases with time, allowing cellular uptake of higher molecular weight 
fluorescent dyes such as ethidium bromide (molecular weight 394) or Yo-Pro-1 (molecular weight 
629). This phenomenon has been attributed to the formation of large cytolytic pores in the plasma 
membrane, leading to cell death (Pelegrin and Surprenant, 2009; Virginio et al., 1999). This time-
dependent increase in permeability has been ascribed to two contrasting mechanisms. The first 
model allows the coexistence of two functions (channel and large pore) within a single structure 
(Teixeira et al., 2009) and predicts that a conformational change initially forms a channel permeable 
to small cations, then leading to dilation of the integral P2X7R pore. When ATP at high 
concentration is linked to P2X7R, eliciting cation influx and intracellular signalling cascades, the β-
sheet structure in the TM2 region then assumes a configuration allowing the passage of molecules 
up to 1 KDa, with the channel transiently acting as a large pore. However, P2X7R-mediated pore 
formation was reported to result from a coordinated signalling cascade involving both the p38 
mitogen-activated protein kinase and caspase pathways that is distinct from other cytolytic pore-
forming mechanisms. A selective p38 (mitogen-activated protein kinase) MAPK inhibitor indeed 
potently inhibits receptor agonist BzATP-induced pore formation, without altering P2X7R-
mediated calcium influx or interleukin-1β (IL-1β) release. In contrast, caspase inhibitors attenuate 
both BzATP-induced pore formation and IL-1β release. Taken together, these results support the 
hypothesis that downstream signalling mechanisms, rather than channel dilation, mediate cytolytic 
pore formation after prolonged agonist activation (Donnelly-Roberts et al., 2004). Moreover, pore 
opening does not occur in all cell types and may be dependent upon receptor density (North, 2002). 
P2X7R-mediated changes in calcium influx and pore-opening are species-specific, showing 
different pharmacological properties between recombinant mouse, rat and human P2X7R 
(Donnelly-Roberts and Jarvis, 2007). 
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An alternative mechanism to pore-opening postulates the activation of a distinct channel protein 
permeable to higher molecular weight cations (North, 2002). In this scenario, P2X7R is responsible 
only for permeability to small cations and interacts instead (directly or through second messengers) 
with this distinct channel protein, thereby allowing permeability to larger cations. At present, there 
is no widely accepted hypothesis to explain this phenomenon, and evidence for and against these 
two models has been forthcoming. A study by Marques-da-Silva et al. (2011) shows that colchicine, 
independently from disruption of cytoskeletal microtubules, inhibits P2X7R-dependent dye uptake 
without affecting receptor channel ionic currents, thus supporting the hypothesis of a distinct 
permeation pathway for high MW dyes. However, the molecular nature of this permeation pathway 
remains unknown. One of the P2X7R activated pore pathways has been attributed to the opening of 
pannexin-1 (Panx1) hemichannels, allowing the passage of ions and small molecules such as ATP 
between the intracellular and the extracellular space (Pelegrin and Surprenant, 2006). This permits 
further P2X7R activation and induces physiological responses such as spreading of cytoplasmic 
calcium waves. In particular, the release of ATP through the interaction between Panx1 and P2X7R 
leads to the release of IL-1β involved in early stages of innate immunity (Iglesias et al., 2008; 
Pelegrin and Surprenant, 2006). However, transient P2X7R activation and Ca2+ overload can act as 
a death trigger for native mouse macrophages independently from Panx1 recruitment (Hanley et al., 
2012). Gulbransen et al. (2012) using in vivo models of experimental colitis, reported that 
inflammation causes enteric neuron death by activating a neuronal signaling complex composed of 
P2X7R, Panx1 channels, the Asc adaptor protein and caspases. Inhibition of P2X7R, Panx1, Asc or 
caspase activity prevented inflammation-induced neuronal death. Preservation of enteric neurons by 
inhibiting Panx1 in vivo prevented the onset of inflammation-induced colonic motor dysfunction. 
The authors concluded that activation of neuronal Panx1 underlies neuron death.  
Yan and colleagues (2010) have formulated a mathematical model to harmonize the above 
studies. Using P2X7R transfected cells, responses to single applications of increasing 
concentrations of BzATP were analyzed utilizing the Markov state mathematical model. This model 
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reproduced the complex pattern of P2X7R gating, including the initial rise in current (I1) and 
decrease in (I2) amplitude with elevation in agonist concentration, or the transition from biphasic to 
monophasic signalling during repetitive agonist application. All receptor responses to the P2X7R-
specific antagonist AZ10606120 were also reproduced by the model. Based on evidence that the 
P2X7R intrinsic pore can dilate over time in physiological conditions, Yan et al. (2010) modelled 
the channel in terms of mutable symmetry within the trimeric receptor. When no ATP is bound, 
P2X7R is symmetrical and closed. When one ATP is bound, the receptor is distorted in such a way 
as to reduce the affinity of the remaining binding sites and remains closed. Binding of the second 
ATP molecule thus requires a higher concentration but leads to further distortion of the receptor 
(additionally decreasing the affinity of the third site), and to the opening of a low-conductance pore 
permeable to small cations. A five-fold difference in the potency of agonist for (I1) and (I2) rise 
supports the concept of asymmetry, and small amplitude monophasic currents observed at low 
agonist concentrations support the presence of a low-conductance state. When the third ATP binds, 
the symmetry is restored, putatively relieving the mechanical stress, and the receptor is fully 
activated with the pore dilated to the high conductance state. The restoration of symmetry may thus 
facilitate an unknown persistent change of state that is required for dilation (Yan et al., 2010). This 
model would explain the facilitation observed for activation of the P2X7R (Roger et al., 2010), the 
two components of the P2X7R-associated current and the opposite effects of P2X7R on cellular 
functions, such as cell growth and differentiation (occupancy of two ATP binding sites) versus cell 
death (occupancy of 3 ATP binding sites accompanied by pore dilation). 
 
1.2.4.4. P2X7R signaling  
 
In macrophages/monocytes, P2X7R stimulation rapidly activates c-Jun N-terminal kinases 1 
and 2 (Humphreys et al., 2000), extracellular signal-regulated kinase (ERK-1/2), and p38 MAPK 
(Aga et al., 2002). The P2X7R agonist BzATP activates the same pathways in mouse N9 microglia 
(Potucek et al., 2006), and increases the nuclear translocation of NF-κB in mouse BV-2 microglia 
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(Potucek et al., 2006). Dephosphorylation of NFAT (nuclear factor of activated T cells) by 
calcineurin exposes a nuclear localization sequence, permitting nuclear translocation and 
transcriptional activation (Rao et al., 1997). In N9 cells, ATP activates NFAT via the P2X7R in a 
calcineurin-dependent fashion (Ferrari et al., 1999). The cyclic AMP response element- (CRE-) 
binding protein (CREB), a member of the activating transcription factor 1 family of transcription 
factors, is involved in cytokine gene regulation (Mayr and Montminy, 2001). P2X7R-dependent 
induction of CREB and activating transcription factor 1 phosphorylation occurs in BV-2 cells via an 
MAPK kinase (MEK)/ERK-dependent pathway (Potucek et al., 2006). Activation of activator 
protein-1 (AP-1) is another transcription factor associated with regulation of inflammatory genes 
(Foletta et al., 1998). Multiple members of the c-Fos and c-Jun families dimerize to form AP-1. In 
serum-starved Jurkat T-cells, activation of P2X7Rs induced AP-1 DNA binding activity as a result 
of increased c-Jun and c-Fos expression (Budagian et al., 2003). ATP treatment also increased the 
phosphorylation of ERK-1/2 and c-Jun N-terminal kinases 1 and 2, but not p38 MAPK, providing a 
potential mechanism for these effects (Figure 4). 
Stimulation of P2X7Rs increases protein tyrosine phosphorylation (Adinolfi et al., 2003; 
Watters et al., 2001) ultimately leading to MAPK pathway activation. Many events downstream of 
P2X7R activation are dependent upon extracellular calcium influx (Ferrari et al., 1999; North, 
2002), and activation of MAPK pathways by P2X7Rs may involve calcium signaling. In RAW 
264.7 macrophages, the calcium-dependent kinase Pyk2, which facilitates Ras activation, is tyrosine 
phosphorylated in response to treatment with BzATP (Aga et al., 2004; Watters et al., 2001), 
potentially linking calcium fluxes, Ras activation, and MAPK pathways with P2X7Rs. P2X7Rs also 
induce the activation of other small molecular weight G-proteins. For example, the Rho/p38 
pathway may be involved in the shedding of IL-1β-containing vesicles (Pfeiffer et al., 2004) 
through actin filament reorganization and membrane blebbing (MacKenzie et al., 2004; Pfeiffer et 
al., 2004), conceivably providing a mechanism whereby MAPKs can mediate increased microglial 
pro-inflammatory cytokine release. 
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Figure 4. Schematic depiction of the signal transduction events occurring in microglia following 
P2X7R activation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extracellular calcium influx triggered by activation of ionotropic P2X7Rs leads to activation of 
calcineurin and dephosphorylation/activation of NFAT (nuclear factor of activated T cells). P2X7R 
activation also results in activation of phospholipases A2 and D (PLA2, PLD), as well as tyrosine 
phosphorylation (P-Tyr) and activation of mitogen-activated protein kinase (MAPK) pathway 
proteins (MAPK kinase, MEK; extracellular signal-regulated kinase, ERK). The latter can then 
influence the activity of transcription factors like NF-κB (nuclear factor-κB), CREB (cyclic AMP 
response element (CRE)-binding protein), and AP-1 (activator protein-1) which upregulate 
expression of pro-inflammatory genes, such as cyclooxgenase-2 (COX-2) and inducible nitric oxide 
synthase (iNOS). Activation of P2X7Rs also leads to p38 MAPK activation with consequent 
phosphorylation/activation of CREB. Broken lines indicate multistep pathways. 
 
     (Taken from Skaper and Giusti, Cardiovasc. Psychiatry Neurol. 2009) 
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1.2.4.5. Function  
 
The P2X7R engages several disparate functions in many distinct cell populations, or even in the 
same cell type, comprising a complex role in the nervous system and neuroinflammation (Duan and 
Neary, 2006; Le Feuvre et al., 2002, Skaper et al., 2010; Weisman et al., 2012). From basic 
extracellular ATP binding, protein oligomerization and pore complex assembly, ATP-gated ion 
channel transport and conductance, membrane depolarization, and calcium signalling, the functions 
of P2X7R extend to lipopolysaccharide (LPS) binding, regulation of MAPK kinase cascades, 
caspases and phospholipases, production of free radicals, and IL-1β secretion. While LPS is an 
efficient stimulus for IL-1β release, rodent microglial cells secrete predominantly the inactive 33-
kDa precursor of IL-1β in response to LPS (Chauvet et al., 2001). Indeed, activation of P2X7R is 
one of the most powerful stimuli for secretion of IL-1β in its mature form (Ferrari et al., 2006; 
Perragaux and Gabel, 1994). However, ATP is an efficient stimulus for IL-1β secretion only after 
the cells have undergone a short 'priming' with LPS (Ferrari et al., 1997b, 2006; Sanz and Di 
Virgilio, 2000). The priming response may be relevant for neuroinflammation, as tissue injury can 
activate Toll-like receptors (TLRs), including TLR4, on glia (Casula et al., 2011). 
Specifically within different tissues, P2X7R can then regulate cell cycle, apoptosis, lysis of 
antigen-presenting cells and killing of foreign cells, T cell maturation, activation of innate immune 
responses, epithelial secretion, regulation of bone resorption and mineralization, fast synaptic 
transmission, sensory perception of pain, as well as playing a role in neurological diseases. Since its 
discovery in lymphocytes and mast cells (Cockcroft and Gomperts, 1979; Keller, 1996), the P2X7R 
has been viewed as a key mediator of inflammation and immunity (Arulkumaran et al., 2011; Di 
Virgilio, 1995; Surprenant et al., 1996). Rassendren et al. (1997) indeed found that treatment of 
cloned P2X7R-transfected human embryonic kidney cells and human macrophages with ATP or 
BzATP elicited cation-selective currents, while longer agonist application caused noxious 
permeabilization of the cells, thus establishing a toxic role for the receptor. In the nervous system, 
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mRNA encoding P2X7R was detected by situ hybridization in excitatory synaptic terminals in CA1 
and CA3 regions of rat hippocampus targeting dendrites of pyramidal cells and parvalbumin-
labelled structures, and regulating the release of glutamate and γ-aminobutyric acid. P2X7R mRNA 
has also been detected in hippocampal inhibitory neurons (Sperlágh et al., 2002). Sugiyama et al. 
(2002) provided evidence that P2X7R activation in rat retinal microvessels triggers apoptosis with 
lethal consequences. Lemaire et al. (2006), using rat lung alveolar macrophages expressing native 
P2X7R and human embryonic kidney cells ectopically expressing full-length rat P2X7R or a C-
terminally truncated P2X7R mutant, showed that the P2X7R is involved in the fusion process 
leading to multinucleated giant cells. This process contributes to many important biological 
mechanisms in mammals during both normal processes and disease such as the development of 
multinucleated osteoclasts during bone resorption, or the fusion of macrophages during 
granulomatous inflammation.  
Apart from the detrimental functions ascribed to P2X7R, trophic properties apparently coexist. 
Depending on its level of activation, P2X7R may induce cell proliferation or apoptosis. For 
example, P2X7R activation has been correlated with disease severity in B-cell chronic lymphocytic 
leukaemia due to cell cycle stimulation, together with increased intracellular calcium fluxes, plasma 
membrane depolarization, formation of a nonselective membrane pore and proliferation in 
neuroblastoma cell lines (Raffaghello et al., 2006). In microglia, using a P2X7R mutant (P2X7R-
G345Y) with intact channel function but ablated pore-forming capacity, Monif et al. (2009) 
provided evidence that the trophic effects of P2X7R expression are exclusively mediated by pore 
conductance and not by the cation channel. Moreover, the authors reported that P2X7R over-
expression, in the absence of pathological insults, was sufficient to drive activation and proliferation 
of microglia in rat primary hippocampal cultures; culture treatment with the antagonist oxidized 
ATP significantly decreased the number and activation of microglia. Ortega et al. (2011) 
demonstrated that stimulation of cerebellar granule neurons with BzATP, similarly to brain-derived 
neurotrophic factor, increased ERK1/2 phosphorylation and protected from excitotoxic 
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concentrations of glutamate, indicating that P2X7R shares survival pathways with trophic factors. 
Using a selective P2X7R antagonist and small interfering RNA knockdown of P2X7R, Thompson 
et al. (2012) reported a pro-survival role in mouse embryonic stem cells in the presence of leukemia 
inhibitor factor. However, chronic exposure to exogenous ATP still led to rapid P2X7R-dependent 
necrotic cell death. Further, these data demonstrate the dual role for P2X7R as a pro-survival or pro-
death signal, depending on its mode of activation. Finally, when the C-terminal truncated P2X7R 
splice variant (also called isoform B or ΔC) that is widely distributed especially in human immune 
and nervous systems, was over-expressed in HEK293 cells, it mediated ATP-stimulated channel 
activity but not plasma membrane permeabilization, raised endoplasmic reticulum Ca2+ content, 
increased the cellular ATP pool and especially stimulated growth. Consistently, P2X7R expression 
increased after mitogenic stimulation of peripheral blood lymphocytes (Adinolfi et al., 2010).  
 
1.2.4.6. P2X7R and pathological states 
 
1.2.4.6.1. Polymorphisms in human diseases  
 
The P2X7R gene is highly polymorphic with many single nucleotide polymorphisms (SNPs) 
affecting receptor function and activity having been documented (www.ncbi.nlm.nih.gov/SNP). For 
example, a role for P2X7R has been demonstrated in susceptibility to infections with intracellular 
pathogens such as tuberculosis. Saunders et al. (2003) found that neither apoptosis nor killing of 
mycobacteria occurred after brief exposure to ATP in macrophages from individuals homozygous 
for inheritance of the 1513A>C loss-of-function polymorphic variant of P2X7R, resulting in the 
glu496-to-ala (E496A) substitution. E496A mutation moreover confers increased lifetime risk of 
extra-pulmonary tuberculosis (Fernando et al., 2007; Niño-Moreno et al., 2007). A recent study on 
papillary thyroid carcinoma revealed strong association between E496A polymorphism and 
follicular variant of this carcinoma (Dardano et al., 2009). Cabrini et al. (2005) noted that in patients 
affected by chronic lymphocytic leukaemia, several other polymorphisms in addition to E496A 
cause receptor loss of function. Moreover, these authors established that the 489C-T polymorphism, 
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which causes a His155-to-Tyr (H155Y) change in the extracellular portion of the receptor, 
corresponds instead to a gain-of-function polymorphism as assessed both by [Ca2+]i influx and 
ethidium bromide uptake. The P2X7R plays a role also in bone homeostasis and disease, and recent 
studies have suggested its function as a mechano-transducer in osteocytes. Inheritance of loss-of-
function P2X7R variants E496A and I568N (Ile568-to-Asn) is associated with increased bone 
fracture risk in post-menopausal females (Ohlendorff et al., 2007; Nissen et al., 2009). Allelic, 
genotypic or family-based case-control association studies using synonymous and non-synonymous 
SNPs revealed P2X7R as a susceptibility gene in the nervous system for mood disorders. Three 
studies with a total of 2,500 patients with bipolar or major depressive disorders found disease 
association with a non-synonymous SNP (rs2230912) within the coding region of the P2X7R gene. 
This SNP codes for Gln460-to-Arg (Q460R) substitution in the carboxyl terminus of the receptor 
that is conserved between humans and rodents and is essential for receptor function (Barden et al., 
2006; Lucae et al., 2006; McQuillin et al., 2009). Finally, a recent study found that P2X7R gene 
variants resulting in receptor gain-of-function display increased frequency in multiple sclerosis 
(Oyanguren-Desez et al., 2011).  
 
1.2.4.6.2. Animal models 
 
Studies on animal models lacking the P2X7R derive from two different strains of P2X7R 
knockout (KO) mice generated by Solle et al. (2001) and Chessell et al. (2005), respectively. Solle 
and colleagues generated their mice by inserting a neomycin cassette into exon 13, replacing a 
region that encodes Cys-506–Pro-532 of the intracellular C terminus of the receptor. In the mouse 
line generated by Chessell and coworkers, the P2X7R gene was knocked out by insertion of a lacZ 
transgene into exon 1. The former model demonstrated P2X7R involvement in bone formation, 
inflammation, and mood disorders, while the study by Chessell et al. (2005) established a role for 
the receptor in inflammatory and neuropathic pain. While the P2X7R was knocked out in both 
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mouse strains, at least two functional receptor splice variants seem to have escaped deletion in these 
KO mice. The P2X7R splice variant with an alternative intracellular N-terminus and first 
transmembrane domains (expressing increased agonist sensitivity and higher propensity to form 
permeable pores) escapes inactivation (Nicke et al., 2009). On the other hand, the KO mice utilized 
by Solle et al. (2001) are not completely null for P2X7R expression but express C-terminal 
truncated (ΔC) variants of the receptor with reduced function (Masin et al., 2012).  
Macrophages from the mutant mice of Solle et al. (2001) failed to respond to extracellular ATP, 
as measured by fluorescent dye accumulation. In addition, after ATP or LPS stimulation, 
macrophages from these P2X7R-deficient mice produced levels of cyclooxygenase-2 and 
accumulated 35-kD pro-IL-1β in amounts comparable to wild-type mice, but did not secrete the 
mature 17-kD IL-1β form, due to impaired post-translational processing. Likewise, mutant mice 
primed with LPS and challenged with ATP failed to generate significant levels of IL-1β, but not of 
IL-6, by impairment of cytokine signalling cascades (Solle et al., 2001). Absence of the P2X7R 
gene moreover alters leukocyte function and attenuates inflammatory responses (Labasi et al., 
2002). P2X7R KO mice also demonstrate a unique skeletal phenotype that involves deficient 
periosteal bone formation together with excessive trabecular bone resorption (Ke et al., 2003). Lack 
of P2X7R prevents ATP-evoked γ-aminobutyric acid and glutamate release in the hippocampus 
(Papp et al., 2004) and microglia activation by amyloid β-peptide (Sanz et al., 2009), but does not 
change survival rate or depletion of striatal endogenous dopamine content after in vivo 
dopaminergic toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) or in vitro rotenone 
treatment (Hracskó et al., 2011). P2X7R-/- mice are resistant to contact hypersensitivity, and 
injection of IL-1β restores the capacity to develop contact hypersensitivity. P2X7R-/- dendritic cells 
also fail to release IL-1β in response to LPS and ATP, suggesting that the P2X7R is a crucial 
receptor for extracellular release of ATP and IL-1β in skin in response to contact allergens (Weber 
et al., 2010). Absence of P2X7R gene moreover has protective effects in different experimental 
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models of lung inflammation (Lucattelli et al., 2011; Monção-Ribeiro et al., 2011; Muller et al., 
2011; Riteau et al., 2010), affects fluid secretion in pancreas, salivary glands and tear glands (Novak 
et al., 2010), exhibits an antidepressant-like profile (Basso et al., 2009) and shows a mood-
stabilizing phenotype alleviating stress-induced responses in several behavioural models (Csölle et 
al., 2012).  
Chessell et al. (2005) showed that chronic inflammatory (in an adjuvant-induced model) and 
neuropathic (in a partial nerve ligation model) hypersensitivity was completely absent to both 
mechanical and thermal stimuli, while normal nociceptive processing was preserved in P2X7R-/- 
mice. Although KO mice were still able to produce pro-IL-1β mRNA, release of IL-1β and IL-10 
was impaired, with systemic reductions in adjuvant-induced increases in IL-6 and monocyte 
chemotactic protein-1 (Chessell et al., 2005). Conversely, Hansen et al. (2011) found that BALB/cJ 
P2X7R-deficient mice were susceptible to bone cancer pain and, moreover, had an earlier onset of 
pain-related behaviours compared to cancer-bearing wild-type mice. These findings support the 
notion that bone cancer pain is a separate pain state compared with neuropathic and inflammatory 
pain. Finally, lack of P2X7R gene attenuated renal injury in experimental glomerulonephritis 
(Taylor et al., 2009). Physiopathological correlations of altered P2X7R gene or protein expression 
are summarized in Table 2. 
 
1.2.4.6.3. Neurodegenerative movement disorders 
 
Parkinson’s disease (PD) and Huntington’s disease (HD) are the two most common chronic 
progressive neurodegenerative movement disorders. PD is characterized by the degeneration of 
dopaminergic neurons in the substantia nigra pars compacta and the presence of protein inclusions 
called Lewy bodies. HD, on the other hand, is associated with atrophy of the striatum and cerebral 
cortex, which leads to a loss of motor control, deterioration in cognitive function, and dementia 
(Burnstock, 2008). 
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Mitochondrial dysfunction and neuroinflammation have been implicated in PD 
pathophysiology. Midbrain astrocytes have been described to express the P2X7R, and exposure to 
rotenone (a mitochondrial poison and PD model) increased receptor current density and inhibited 
the secretion of TNF-α (Gao et al., 2011). In a study by Hracskó et al. (2011), in vivo 1-methyl-4-
phenyl-1,2,3,6- tetrahydropyridine treatment (a dopaminergic toxin and model of PD) increased the 
mRNA expression of P2X7R in the striatum and substantia nigra of wild-type mice. Genetic 
deletion or pharmacological inhibition of P2X7R, however, did not change survival rate or 
depletion of striatal endogenous dopamine content after 1-methyl-4-phenyl-1,2,3,6- 
tetrahydropyridine treatment. 
There is little information on a potential role for the P2X7R in HD, although in one study 
increased P2X7R levels and altered receptor-mediated calcium permeability in somata and 
terminals of neurons from HD mutant mice was observed (Díaz-Hernández et al., 2009). 
Furthermore, cultured neurons expressing mutant huntingtin showed increased susceptibility to 
apoptosis triggered by P2X7R stimulation. In vivo administration of the P2X7R-antagonist Brilliant 
Blue-G to HD mice prevented neuronal apoptosis and attenuated body weight loss and motor-
coordination deficits, suggesting that altered P2X7R levels and function contribute to HD 
pathogenesis.  
 
1.2.4.6.4. Epilepsy and neuropsychiatric disorders 
 
PanX1, a vertebrate homologue of the invertebrate innexin gap junction proteins, acts as a 
channel and can be opened at the resting membrane potential by ATP via the P2X7R, as previously 
described. Besides causing cell death, Panx1 opening induces aberrant bursting in vitro (Thompson 
et al., 2008). It has been suggested that the P2X7R-Panx1 complex may play an important role as a 
negative modulator of muscarinic acetylcholine M1 receptor-mediated seizure activity in vivo, as 
P2X7R KO mice showed greater susceptibility to seizures induced by pilocarpine, an M1 receptor  
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Table 2. Physiopathological correlations of altered P2X7R gene or protein expression 
 
Variation Tissue/Cell Physiopathological Action(s) Reference(s) 
Gene deletion  macrophages, microglia defective IL-1β release, 
 
defective intraphagosomal killing 
Solle et al. (2001) ; 
Sanz et al. (2009) ; 
Fairbairn et al. 
(2001) 
 joint tissue reduced experimental arthritis Labasi et al. (2002) 
 long bones defective bone homeostasis Ke et al. (2003) 
 cornea epithelial migration and stromal organization Mayo et al. (2008) 
 lung reduced smoke-induced lung inflammation Lucattelli et al. 
(2011) 
 liver reduced autoimmune hepatitis Kawamura et al. 
(2006) 
 kidney 
 
reduced inflammation and fibrosis following 
ureteral obstruction,  
reduced experimental glomerulonephritis  
Gonçalves et al. 
(2006) 
Taylor et al. (2009) 
 brain  
 
defective experimental encephalomyelitis,  
anti-depressant-like behaviour,  
spatial memory impairment,  
mood-stabilizing phenotype 
Sharp et al. (2008); 
Basso et al. (2009);  
 Labrousse et al. 
(2009) 
Csölle et al (2012) 
 nervous system reduced neuropathic pain Chessell et al. 
(2005) 
    
RNA interference  mouse microglia 
 
decreased proliferation Bianco et al. 
(2006) 
 rat spinal cord reduced long term potentiation and allodynia Chu et al. (2010) 
    
Upregulation human neuroblastoma cells Carcinomas Raffaghello et al. 
(2006) 
 human spinal cord and 
cerebral cortex 
amyotrophic lateral sclerosis,  
 
 
 
multiple sclerosis  
Yiangou et al. 
(2006); D'Ambrosi 
et al. (2006) 
Amadio et al. 
(2010,2011) 
 human B lymphocytes chronic lymphocytic leukaemia Adinolfi et al. 
(2002) 
 human kidney autosomal recessive polycystic kidney disease Hillman et al. 
(2004) 
 mouse kidney experimental diabetes/hypertension Vonend et al. 
(2004) 
 mouse microglia genetic model of Alzheimer’s disease Parvathenani et al. 
(2003) 
 rat hippocampus, striatum 
and frontoparietal cortex 
hypoxic/hypoglycaemic damage and perinatal 
rat asphyxia  
 
Cavaliere et al. 
(2004); Melani et 
al. (2006); Frizzo 
et al. (2010) 
 mouse retina   retinal degeneration Franke et al. 
(2005) 
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agonist, than their wild-type littermates (Kim and Tang, 2011). Further, administration of P2X7R 
antagonists and gene silencing of P2X7R or Panx1 in wild-type mice increased pilocarpine-induced 
seizure susceptibility (Burnstock, 2007; but see Engel et al., 2012). 
The case for P2X7R gene association with neuropsychiatric diseases is controversial. Several 
linkage and association studies have claimed an association with bipolar- and unipolar affective 
disorders (McQuillin et al., 2009; Soronen et al., 2011) and depression (Burnstock et al., 2011; 
Hejjas et al., 2009; Lucae et al., 2006). In addition, P2X7R KO mice are reported to display 
alteration in mood-related behaviour (Csölle et al., 2012) an anti-depressant-like profile, but no 
significant differences between genotypes were observed in models of anxiety (Basso et al., 2009). 
In contrast, other studies have failed to find association between P2X7R gene polymorphisms and 
major affective disorders (Grigoroiu-Serbanescu et al., 2009; Viikki et al., 2011).  
 
1.2.4.6.5. Amytrophic lateral sclerosis and multiple sclerosis  
 
Amyotrophic lateral sclerosis (ALS) is characterized by the progressive degeneration of motor 
neurons in the spinal cord, brainstem and motor cortex, leading to respiratory failure and death of 
affected patients within a few years from diagnosis (Cozzolino et al., 2012). The discovery of 
mutations in the gene encoding the antioxidant enzyme Cu/Zn superoxide dismutase-1 (SOD1) in a 
subset of patients with familial ALS has led to the development of transgenic animal models 
expressing different SOD1 mutations (Gurney, 1997). Accumulating evidence indicates that non-
neuronal cells contribute to motor neuron dysfunction and death in ALS, by the maintenance of a 
chronic inflammatory response (Boillée et al., 2006). Extracellular ATP levels markedly increase in 
the nervous system in response to ischemia, trauma and inflammatory insults (Burnstock, 2008), 
although the situation in ALS has not been studied. In ALS patients as well as SOD1G93A animals, 
increased immunoreactivity for P2X7R has been found in spinal cord microglia (Yiangou et al., 
2006). Furthermore, SOD1G93A microglia in culture display an increased sensitivity to ATP, and 
P2X7R activation drives a pro-inflammatory activation that leads to decreased survival of neuronal 
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cell lines (D'Ambrosi et al., 2009). Moreover, P2X7R activation in spinal cord astrocytes has been 
described to initiate a neurotoxic phenotype that leads to motor neuron death (Gandelman et al., 
2010). The neurotoxic phenotype of SOD1G93A astrocytes depended upon basal activation of the 
P2X7R. 
Multiple sclerosis (MS) is a chronic, degenerative disease of the CNS, which is characterized 
by focal lesions with inflammation, demyelination, oligodendroglial death and axonal degeneration 
(Nylander and Hafler, 2012). Although the etiology of the disease is still unknown, both genetic and 
environmental factors contribute to MS susceptibility. In addition, blockade of P2X7R prevents 
ATP excitotoxicity to oligodendrocytes and ameliorates experimental autoimmune 
encephalomyelitis (Matute et al., 2007) also in a P2X7R KO model (Sharp et al., 2008). Increased 
P2X7R immunoreactivity has been observed in post-mortem spinal cord microglia of MS patients 
(Matute et al., 2007; Yiangou et al., 2006) (Figure 5). From a therapeutic perspective, a new study 
reports that glatiramer acetate modulates monocyte P2X7R expression in MS (Caragnano et al., 
2012).  
 
1.2.4.6.6. Neuroblastoma 
 
Neuroblastoma is the most common extracranial tumor of childhood, derived from the 
sympathetic nervous system, often characterized by low response to conventional treatments and 
poor prognosis. P2X7R is expressed in neuroblastoma primary tumors and cell lines (Raffaghello et 
al., 2006; Sun, 2010), and functional activation by ATP is coupled to massive increases in cytosolic 
calcium, membrane depolarization, and uptake of larger hydrophilic molecules. Further, P2X7R 
stimulation by ATP induces early morphologic changes without signs of apoptosis and late increase 
of cell proliferation mediated by substance P secretion (Raffaghello et al., 2006), suggesting that 
neuroblastoma cells have shaped P2X7R function to their advantage. 
 
 
 48 
Figure 5. P2X7R levels are increased in multiple sclerosis 
 
 
A, Hoechst (top) and immunofluorescence staining of oligodendrocytes (APC+ cells) with 
antibodies to P2X7Rs in the human optic nerve from controls and normally appearing multiple 
sclerosis (MS) samples. Merge images show that P2X7Rs are located in oligodendrocytes in both 
control (C) and multiple sclerosis samples. In turn, cells of the microglial lineage (CD68+) also 
show P2X7R immunolabeling. Scale bar, 20 μm. B, Western blot of optic nerve homogenates from 
sex- and age-matched controls (C) and multiple sclerosis cases. Sample loading was normalized to 
the intensity of bands corresponding to actin. From Matute et al. (2007), Fig. 5. 
 
 
1.2.4.6.7. Alzheimer’s disease 
 
Alzheimer’s disease (AD), the most common cause of dementia, is characterized 
histopathologically by the appearance of senile plaques composed of the amyloid β-peptide (Aβ) 
and neurofibrillary tangles containing hyperphosphorylated tau protein. The cause for most AD 
cases is still essentially unknown (except for 1% to 5% of cases where genetic differences have 
been identified), although inflammation is believed to be an important component of the 
etiopathology. Increased expression of P2X7R mRNA has been described in AD-derived microglia 
compared to non-demented brain, along with prominent P2X7R protein immunoreactivity in 
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association with Aβ plaques and localized to HLA-DR-immunoreactive microglia (McLarnon et al., 
2006). Intrahippocampal injection of Aβ in rats resulted in strong P2X7R colocalization with 
microglia (McLarnon et al., 2006) and accumulation of IL-1β in wild-type, but not in P2X7R-
deficient mice (Sanz et al., 2009). In a genetic mouse model of AD, the P2X7R was predominantly 
expressed in CD11b-immunopositive microglia from 3 months of age before Aβ plaque formation 
(Lee et al., 2011). A catalytic subunit of NADPH oxidase, gp91phox, was detected in P2X7R–
positive microglial cells of 6-month-old animals, suggesting the potential for P2X7R-positive 
microglia to generate reactive oxygen species. Damaged postsynaptic density 95-positive dendrites 
(‘synaptotoxicity’) were found in regions positive for P2X7R in the cerebral cortex of 6-month-old 
mice (Lee et al., 2011). 
 
1.2.4.6.8. Brain ischemia 
 
ATP outflow increases after an ischemic insult in the brain, which could activate P2X receptors. 
Several studies have reported increased P2X7R expression, by immunohistochemistry and Western 
blot, in the peri-infarct region after middle cerebral artery occlusion in rats (Franke et al., 2004; 
Melani et al., 2006; Yanagisawa et al., 2008). P2X7R antagonists such as Brilliant Blue G reduced 
the extent of brain damage (Arbeloa et al., 2012; Melani et al., 2006) and improved sensorimotor 
deficit in ischemic animals (Melani et al., 2006). However, Le Feuvre et al. (2003) found that cell 
death induced by temporary cerebral ischemia was not altered in P2X7R KO mice, but was reduced 
by treatment with IL-1 receptor antagonist. Treatment of mice with P2X7R antagonists did not 
affect ischemic or excitotoxic cell death, suggesting that P2X7R is not a primary mediator of 
experimentally induced neuronal death. In a more recent study, Yanagisawa el al. (2008) reported 
that intracerebroventricular injection with the P2X7R agonist BzATP improved behavioural 
dysfunction and ischemic neural injury induced by middle cerebral artery occlusion, while the 
P2X7R antagonist adenosine 5'-triphosphate-2',3'-dialdehyde exacerbated ischemic brain damage. 
Collectively, these results leave open the question of P2X7R as 'friend or foe' in brain ischemia.  
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 1.2.4.6.9. Neuropathic and inflammatory pain 
 
Activation of P2X receptors in the spinal cord was shown to elicit allodynia (Fukuhara et al., 
2000) and in a seminal publication in 2003, P2X4R on spinal cord microglia was shown to be 
upgraded in neuropathic pain, which was reduced after P2X4R antagonism (Tsuda et al., 2003). An 
explosion of work then followed and P2X7R and P2Y12R on microglia were also shown to be 
involved in neuropathic pain (Jarvis, 2010; Smith, 2010; Tsuda et al., 2010). However, the 
underlying mechanism whereby antagonists to P2X7R, P2Y12R, as well as P2X4R all reduce 
neuropathic pain is still unclear. The selective antagonists to P2X7R, A-438079 and A-740003 
produced dose-dependent antinociceptive effects in models of neuropathic (Honore et al., 2006, 
McGaraughty et al., 2007; Nelson et al., 2006) (Figure 6) and inflammatory (Honore et al., 2006) 
pain, as did Brilliant Blue G (He et al., 2012), cyanoguanidine (Perez-Medrano et al., 2009) and A-
839977 (Honore et al., 2009). It has also been suggested that P2X7R plays a role in neuron-glial 
interactions associated with ongoing pain (Donnelly-Roberts et al., 2007). Chronic inflammatory 
and neuropathic pain, and also release of the inflammatory cytokine IL-1β, was abolished in P2X7R 
KO mice (Chessell et al., 2005) (Figure 7). The authors suggested that the P2X7R, via regulation of 
mature IL-1β production played an upstream transductional role in the development of neuropathic 
and inflammatory pain (Clark et al., 2010). In recent studies, P2X7R was shown to be associated 
with TNF-α production in microglia through the p38-mitogen-activated protein kinase system and 
treatment with inhibitors of either TNF-α or p38 resulted in reduction of allodynia (Leung and 
Cahill, 2010; Teixeira et al., 2010). P2X7R expressed by immune cells plays a pivotal role in 
changing pain thresholds (Chessell et al., 2005). Sorge et al. (2012) recently showed that variation 
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Figure 6. Antinociceptive effects of A-740003 in the spinal nerve ligation model of neuropathic pain 
 
 
Two weeks following L5-L6 spinal nerve injury, A-740003 was injected i.p. 30 min before testing. A-
740003 demonstrated significant antiallodynic effects in neuropathic pain [F(5,152) = 109.42, p < 0.0001]. 
Data represent mean ± S.E.M. **, p < 0.01 as compared with vehicle-treated animals (n = 6–12 per group). 
From Honore et al. (2006), Fig. 8. 
 
 
Figure 7. Responses to noxious thermal and mechanical stimuli in P2X7R+/+ and P2X7R−/− mice 
following partial nerve ligation 
 
 
(a) Following ligation, thermal hypersensitivity developed after 3 days in P2X7R+/+ animals, and was 
significantly different from pre-surgery values for at least 21 days. In P2X7R−/− animals, hypersensitivity 
completely failed to develop. (b) P2X7R+/+ mice developed significant mechanical hypersensitivity 3–7 days 
following ligation, which was maintained until day 21. P2X7R−/− mice completely failed to display any 
significant hypersensitivity at any time point studied. From Chessell et al. (2005), Fig. 2. 
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within the coding sequence of the P2X7R gene affects chronic pain sensitivity in both mice and 
humans. Using genome-wide linkage analyses, they discovered an association between nerve 
injury–induced pain behavior (mechanical allodynia) and the P451L mutation of the mouse P2X7R 
gene. Mice with this mutation impairing calcium influx and pore formation also showed less 
allodynia than mice with the pore-forming P2X7R allele. Administration of a peptide corresponding 
to the P2X7R C-terminal domain, which blocked pore formation but not cation channel activity, 
selectively reduced nerve injury and inflammatory allodynia only in mice with the pore-forming 
P2X7R allele (Sorge et al., 2012). While this variant has been reported to be non-functional in this 
model, the P451L mutation found in C57BL/6 mice is instead fully functional and 
pharmacologically indistinguishable from wild-type P2X7R when expressed in human astrocytoma 
1321N1 cells (Donnelly-Roberts et al., 2009). This of course becomes relevant in terms of human 
therapeutics. Moreover, in two independent human chronic pain cohorts a genetic association was 
observed between lower pain intensity and hypofunctional His270 (rs7958311) allele of P2RX7. 
Selectively targeting P2X7R pore formation may be a new strategy for the treatment of chronic pain 
(Sorge et al., 2012).  
 
1.2.4.6.10. Cardiovascular disorders 
 
Apoptotic cell death occurs in a number of vascular diseases, including atherosclerosis and 
hypertension (Mallat and Tedgui, 2000). Shear stress that occurs during changes in blood flow 
causes a substantial release of ATP from vascular endothelial cells (Burnstock, 1999). ATP may 
also be released from cardiomyocytes in ischemic or hypoxic conditions (Dutta et al., 2004). 
P2X7R-associated production of proinflammatory cytokines like tumor necrosis factor-α could 
promote endothelial cell apoptosis (Alesci et al., 2005), and play a role in vascular remodeling in 
hypertension (Gibbon, 1993). P2X receptor channels are involved in transducing 
aldosteronemediated signaling in the distal renal tubule and are potential candidate genes for blood 
pressure regulation (Zhang et al., 2007). On an intriguing note, there is evidence to suggest that 
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elevated night-time diastolic blood pressure is associated with single nucleotide polymorphisms of 
the P2X7R gene (Palomino-Doza et al., 2008). P2X7Rs are expressed in human saphenous vein 
myocytes (Cario-Toumaniantz et al., 1998), and venous diseases may favor conditions allowing 
P2X7R activation and lysis of venous myocytes. ATP released after hypoxia, stress and 
inflammation, or membrane damage, conditions found in the vessel wall of varicose veins, may lead 
to P2X7R-induced pore formation, the disorganization and loss of contractile myocytes in the 
muscle layers of the media of varicose veins, and venous disease. 
Fibroblasts are a key structural element of the arterial wall known to play a major role in 
atherosclerosis and diabetic angiopathy (Duner et al., 1997). Fibroblasts from type-2 diabetes 
patients are characterized by a hyperactive purinergic loop (Solini et al., 2004). 
While depression and cardiovascular co-morbidity have been recognized for some time 
(Glassman, 2007), a pro-inflammatory link has only recently been investigated (Stewart et al., 
2009). Extensive prospective studies are required to confirm this idea, and to investigate whether a 
link exists between illnesses with a pro-inflammatory component (e.g., inflammatory and chronic 
neuropathic pain) and cardiovascular disease, for example, hypertension, and whether patients 
treated with anti-inflammatory drugs have a lower incidence of cardiovascular complications.  
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THESIS AIMS 
Neuroinflammation in nervous system disorders was viewed at one time as an epiphenomenon 
following neuronal cell damage. Emerging evidence now challenges this earlier "neuron-oriented" 
perspective and points to a more active role of neuroinflammation in pathophysiology onset and 
progression, with glia having key roles in conditions from chronic pain and epilepsy to 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis – 
and may even contribute to schizophrenia, depression, and other psychiatric disorders. The 
initiation and propagation of neuroinflammation appears to rely very much on the interaction 
between glia, immune cells. Glial cells, in particular microglia, show increased activity in multiple 
pain processing pathways in response to peripheral injury, and systemic inflammation gives rise to 
signals that communicate with the brain and lead to changes in metabolism and behavior. The 
healthy brain often responds to stress and insults by transiently up-regulating inflammatory 
processes which are kept in check by endogenous protective elements. Upsetting this homeostatic 
balance can result in disease or exacerbation of initiating factors that result in disease. 
This research project was organized around 3 main objectives: 
1. To establish cultures of microglia and astrocytes from neonatal rat cortex, spinal cord 
and cerebellum, and to characterize these cells utilizing immunocytochemical, molecular 
biological, and biochemical techniques, their responses to a well accepted inflammatory 
stimulus (LPS) and ATP, including the functionality of P2X7R ('priming response'); 
2. To understand the interaction between astrocytes and microglia in response to the 
selected inflammatory stimulus (LPS), as well as in the action of P2X7R-mediated IL-
1β release ('priming response'); 
3. To study the generality of the LPS/ATP priming behavior by examining the ability of 
other agents linked to neuropathology, to replace either LPS or ATP. These will include 
ethanol, amyloid β-peptides, and agonists of TLR2 and TLR3. 
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2. MATERIALS AND METHODS 
2.1. Cell culture 
2.1.1. Equipment and labware 
1. Stereo dissecting microscope (backlighting of stage is preferred) with fiber optic light source 
2. Horizontal flow cabinet for dissections 
3. Laminar flow biological safety cabinet (CL2) 
4. Humidified, water-jacketed culture incubator at 37°C and 5% CO2/95% air 
5. Water bath set at 37°C 
6. Dissecting tools 
7. Bench centrifuge to accommodate 15 mL and 50 mL tubes 
8. Orbital shaker with enclosed, temperature controlled chamber 
9. 10 cm ∅ sterile tissue culture dishes (any supplier) 
10. 15 mL and 50 mL polypropylene plastic centrifuge tubes (sterile) 
11. Sterilin 10 cm ∅ sterile petri plastic dishes (Bibby-Sarstedt) 
12. Tissue culture flasks (T-75; 75cm2) with canted neck and 0.2 µm vented cap (Corning) or 
without vented cap (BD Falcon). 
13. Cell scrapers, 25 cm handle, 1.8 cm blade (BD Falcon) 
14. 0.22 µm filters (Millipore Corporation) 
 
2.1.2. Reagents 
1. Phosphate-buffered saline (PBS) (pH 7.4, sterile) (Invitrogen) 
2. Dulbecco’s modified Eagle’s medium (DMEM) (+4.5 g/L glucose, L-glutamine, pyruvate) 
(Invitrogen) 
3. Trypsin inhibitor (Sigma) 
4. DNAse (Type I) (Sigma) 
5. L-15 medium (+L-glutamine, L-amino acids) (Invitrogen) 
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6. Trypsin inhibitor, type I from soybean (Sigma) 
7. Papain  (Worthington (Lorne)) 
8. Bovine serum albumin, Cohen fraction V (Sigma) 
9. Penicillin/streptomycin (100X stock), sterile, for cell culture (Invitrogen) 
10. Gentamicin (50 mg/mL stock), sterile, for cell culture (Sigma) 
11. Fetal bovine serum (FBS) (Invitrogen) 
12. Poly-L-lysine (MW 70,000-150,000), sterile, for cell culture (Sigma P-6282) 
13. Poly-D-lysine (MW 30,000-70,000), sterile, for cell culture (Sigma P-7280) 
14. Collagen, Type 1 from rat tail (Sigma C-3867) 
15. L-Glutamine (200 mM stock), sterile, for cell culture (Invitrogen) 
16. Sodium pyruvate (100 mM stock), sterile, for cell culture (Sigma) 
17. HEPES (1 M), sterile.for cell culture (Sigma) 
18. LPS (E. coli 026:B6) (Sigma) 
19. Griess Reagent (Sigma) 
20. Adenosine 5’-triphosphate (ATP) (Sigma) 
21. L-Leucine methyl ester HCl (L-LME) (Sigma) 
 
2.1.3. Culture media and other solutions 
1. DNase: Dissolve 40 mg of DNase in 10 mL of L-15 medium (100X stock, 4 mg/mL), filter 
sterilize, aliquot and store at -20°C. 
2.  L-cysteine: Dissolve 24 mg of L-cysteine in 1 mL of L-15 medium (100X stock). Prepare 
fresh each time. 
3. Trypsin inhibitor: Dissolve 100 mg of trypsin inhibitor in 1 mL (100X stock) of L-15 
medium. Filter-sterilize, aliquot and store at -20°C. 
4. Bovine serum albumin: Dissolve 5 mg of bovine serum albumin in 1 mL (100X stock) of 
L-15 medium. Filter-sterilize, aliquot and store at -20°C. 
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5. 0.15 M Borate buffer pH 8.4: Dissolve 28.6 g of sodium borate (Na2B4O7 • 10 H2O) in 500 
mL water (pH will be ∼9.2). Adjust pH to 8.4 with 5N HCl. Filter-sterilize and store at 4°C 
(up to 6 months). 
6. Plating medium/growth (maintenance) medium: To a 500 mL bottle of DMEM add: 50 
mL FBS (10% final), 5 mL stock penicillin/streptomycin (100 U/mL penicillin + 100 µg/mL 
streptomycin final), and 0.5 mL of gentamicin stock (50 µg/mL final). 
 
2.1.4. Preparation of substratum 
1. Dissolve a 5 mL bottle of poly-L-lysine (MW 70,000-150,000) in 5 mL 0.15 M borate 
buffer (pH 8.4). This 1 mg/mL stock solution can be stored at +4°C for up to 2 months. 
2. Dilute the 1 mg/mL stock solution of poly-L-lysine 1:100 (1 mL in 99 mL sterile water) and 
add 10 mL to each of the T-75 culture flasks. Rock the flask to cover the entire culture 
surface and place flask in the 5% CO2 incubator (37°C) overnight. 
3. The following day aspirate the poly-L-lysine coating solution and leave the flask(s) under 
the CL2 cabinet uncapped to dry. This will usually take several hours. Once dried the poly-
L-lysine-coated flasks can be stored at +4°C for one month.  
 
2.1.5. Dissection of rat cortical tissue 
1. Rat cultures are routinely performed using animals at postnatal day 1-2. Following 
appropriate national and institutional guidelines for animal sacrifice, pregnant rats (CD 
strain, Sprague Dawley) are euthanized following approved national and institutional 
guidelines. 
2. Dissect out cerebral hemispheres following standard techniques and anatomical landmarks. 
The procedure is applicable to either rat or mouse pups. 
3. Make an incision under the skin along the midline of the dorsal surface and peel the skin 
back. 
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4. Make a second incision close to the midline along the exposed dorsal surface (the cut should 
be along the complete anteroposterior axis of the lateral ventricles). 
5. Splay open the hemisphere along the cut surface and continue the cut along the dorsal 
surface of the hemisphere. 
6. Remove the cerebral hemispheres (minus cerebellum and brain stem) and peel off meninges. 
The latter step is best accomplished by using two fine-tipped #5 Dumont forceps, using one 
pair to anchor the hemisphere while peeling off the meninges with the second pair. 
7. Place the dissected hemisphere into a separate 10 cm ∅ dish of cold L-15 medium. 
8. Repeat this procedure for the other hemisphere and remaining pups. 
9. The hippocampal area can be dissected away and retained or discarded, depending on need. 
 
2.1.6. Enzymatic digestion of cortical tissue and preparation of cell suspension for plating 
1. Grip a straight edge razor blade with a haemostat, dip in 70% ethanol, and pass through a 
flame to sterilize. 
2.  Mince the collected cortical tissue with the razor blade. 
3. Collect the minced tissue with L-15 and transfer to a 15 mL centrifuge tube. 
4. Centrifuge collected cortical tissue for 30 seconds (200xg) to compact the minced tissue. 
5. While the tissue is centrifuging, prepare the following: 3 mL of L-15 medium containing 
140 µL stock papain solution (as purchased), 30 µL of 100X stock L-cysteine solution, and 
30 µL of 100X DNase stock solution. Filter-sterilize before use. 
6. Remove L-15 medium from the tube with cortical tissue pellet, and add the L-15 solution 
containing papain, DNase, and L-cysteine. 
7. Incubate tissue for 60 minutes in a 37°C water bath with occasional swirling. 
8. During this time, prepare the ovomucoid solution: to 3 mL of L-15 medium add 30 µL of 
100x stock DNase solution, 30 µL of 100X stock bovine serum albumin solution, and 30 µL 
of 100X stock trypsin inhibitor solution. 
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9. Upon completion of the enzyme incubation step remove the supernatant and replace with 1.5 
mL ovomucoid solution. 
10. Incubate for 2 minutes in a 37°C water bath. 
11. Centrifuge at 250xg for 3 minutes. 
12. Remove the supernatant and add 1.5 mL fresh ovomucoid solution. 
13. Triturate 20-25 times with a long (9-inch) cotton plugged Pasteur pipette. 
14. Add 4 mL plating medium and centrifuge at 200xg for 5 minutes. 
15. Using a 5 mL tissue culture pipette, re-suspend the cell pellet in 3 mL plating medium. Add 
an additional amount of plating medium such that the final volume is equivalent to 2 mL x 
number of T-75 flasks to be used (e.g. 20 mL final for 10 flasks). 
16. Add 18 mL plating medium to each flask, followed by 2 mL of cell suspension. Normally, 
we seed cultures at a ratio of 1.5 brains per flask. 
17. The following day, replace the culture medium with 15 mL fresh plating (growth) medium. 
18. Twice per week, replace one-half the volume of culture medium with an equal volume of 
fresh growth medium. 
19. The mixed glial cell cultures are incubated for 7-10 days, after which time confluence will 
have been reached and can be taken for harvesting different cell populations. 
 
2.1.7. Isolation of Microglia 
1. Remove 3 mL medium from each T-75 flask; this should leave about 12 mL of medium. 
2. As the culture medium is bicarbonate buffered, to prevent pH excursions close the flask cap 
(or cover with parafilm if the cap is of the filter type). 
3. Place the flasks on an orbital shaker fitted with a temperature controlled chamber. Flasks 
can be fastened to the shaker platform using double-sided adhesive tape, or taped directly to 
the platform using high strength industrial ducting tape. 
4. Shake the flasks for 1 hour at 200 cycles per minute (37°C). 
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5. Remove the culture medium (containing mainly microglia) from the flasks and transfer to 10 
cm ∅ Sterilin petri plastic dishes. A volume of 20-25 mL per dish is best. 
6. Place the Sterilin dishes in the 5% CO2 incubator (37°C) and leave for 45-60 minutes. 
7. Aspirate the medium on the Sterilin plates and add 6 mL fresh maintenance medium. 
8. Use a cell scraper to remove the attached microglia from the Sterilin dishes. Transfer the 
medium with cells to a 50 mL centrifuge tube. Rinse the dishes with 5 mL maintenance 
medium and transfer to the collection tube. 
9. Re-suspend the microglia cell pellet in maintenance medium and plate into poly-L-lysine-
coated multiwall plates as dictated by the experimental design. Typically, we plate 105 cells 
in a 96 well plate (equivalent to 3.5x105 cells per cm2). Microglia obtained are >99% pure. 
Cultures will maintain their viability for approximately 10 days. 
 
2.1.8. Isolation of an enriched population of astrocytes 
1. The T-75 flasks remaining after shaking to recover microglia are used as a source of highly 
enriched astrocytes. 
2. Aspirate the medium from the flask and rinse the cell monolayer with 10 mL sterile 
phosphate-buffered saline. 
3. Add to the flask 3 mL of 0.25% trypsin/EDTA solution, rock the flask to spread the trypsin 
solution over the entire monolayer, and then remove by aspiration. This will leave a thin 
film of trypsin solution over the cells. 
4. Incubate the flask(s) at 37°C for 10 minutes. 
5. Tap the flask against the palm of the hand to dislodge cells and add 5 mL maintenance 
medium per flask; the FBS in the medium inactivates the trypsin. 
6. Rinse the flask with the medium added, collect cells and transfer to a 15 mL or 50 mL 
centrifuge tube, as needed. 
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7. Pellet cells by centrifugation at 200xg for 5 minutes, re-suspend pellet in maintenance 
medium and count. The typical cell yield is 4-5 x 106 cells per T-75 flask. On this basis, 
dilute the cell suspension to 1-1.5 x 106 cells per mL for ease of counting. Astrocytes thus 
obtained are >95% pure. 
8. If needed, dilute further the cell suspension for plating into poly-L-lysine-coated culture 
vessels are dictated by the experimental design. Typically, we plate 5 x 104 cells in a 96 well 
plate (equivalent to 1.75x105 cells per cm2). 
 
2.1.9. Preparation of spinal cord glia 
1. The procedure is essentially as that described for cortical tissue, except for the dissection. 
2. Sacrifice pups by decapitation. 
3. Place the body face down on a paper towel. Spray 70% ethanol over the back. 
4. Remove the back skin with surgical scissors to expose the vertebral column. 
5. Entering from the anterior side of the body, make a cut through the midline as far as the tail. 
6. Using a fine pair of surgical scissors trim back, at a 45° angle, the tissue on either side of the 
spinal canal (being careful not to disrupt the spinal cord itself). 
7. Carefully strip off the spinal cord with a fine pair of forceps and transfer to a 10 cm ∅ dish 
of cold L-15 medium. 
8. Repeat this procedure for the remaining pups. 
9. Peel off the meninges using fine tipped forceps, and transfer the tissue pieces to a 15 mL 
centrifuge tube. It is not necessary to mince the tissue as for cortex; the spinal cord is much 
smaller, and will already have been fragmented to some extent in the course of removing the 
meninges. 
10. Centrifuge the collected tissue for 30 seconds (200xg) to compact. 
11. Remove L-15 medium from the tube and add the L-15 solution containing papain, DNase, 
and L-cysteine. 
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12. Incubate tissue for 60 minutes in a 37°C water bath with occasional swirling. 
13. Proceed with tissue dissociation as for cortex, except the final 5-minute centrifugation can 
be omitted. Doing so reduces the change of loosing material, which is limited in comparison 
to cortex. 
14. Following dissociation, plate the spinal cord cell suspension in medium and distribute in 
poly-L-lysine-coated T-75 flasks, 5 spinal cords per flask. 
15. For harvesting microglia, we find that spinal cord mixed glia cultures mature more slowly 
than do the cortical cultures. As such, optimal recovery of microglia is achieved after ~10 
days in vitro. Isolation of separate populations of microglia and astrocytes is carried out as 
described for cortical cultures. 
16. Spinal cord astrocytes are seeded onto a collagen substratum (cells will clump and detach if 
poly-lysine is used). 
 
2.1.10. Preparation of cerebellar microglia 
1. Cerebellar tissue from 7-8-day-old rat pups was used. The procedure followed is described 
in detail in our earlier publication (Facci and Skaper, 2012a), and makes use of a 
commercially available papain dissociation kit (Worthington, Lakewood, New Jersey, 
USA).  
2. To favor the growth of glia, the culture medium used was that described above for cortical 
and spinal cord glia. 
 
2.2. Real-time polymerase chain reaction (RT-PCR) 
Microglia and astrocytes were seeded in poly-lysine-coated 12-well plates (collagen-coated for 
spinal cord astrocytes) at a density of 500,000 cells per well, using glia cell growth medium and 
allowed to adhere overnight. Cells were then incubated with LPS for 6 h, and total RNA was 
extracted from cells by TRIzol (Invitrogen), according to the manufacturer’s instructions. RNA 
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integrity and quantity were determined by RNA 6000 Nano assay in an Agilent BioAnalyser. RT 
was performed with Superscript III reverse transcriptase (Invitrogen). The Real-time RT-PCR 
reaction was performed in a MX 3000P thermal cycler in a final volume of 12.5 µL, containing 100 
nM of each primer and 1X SYBR green JumpStart Taq ReadyMix (Sigma-Aldrich). The PCR 
cycling conditions were 4 min of denaturation at 94°C, followed by 45 cycles of denaturation at 
94°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 30 s, followed by a dissociation 
thermal profile of 95°C for 1 min, 55°C for 30 s, and 95°C for 30 s. The following primer pairs 
were used:  
GAPDH, 5'-CAAGGTCATCCATGACAACTTTG-3' F and 5'-GGGCCATCCACAGTCTTCTG-3' 
R (89 bp);  
IL-1β, 5’-TGTGGCAGCTACCTATGTCT-3’ F and 5’-GGGAACATCACACACTAGCA-3’ R 
(146 bp); 
iNOS ((inducible nitric oxide synthase or NOS2), 5’-CACACAGCGCTACAACATCC-3’ F and 5’-
CCATGATGGTCACATTCTGC-3’ R (149 bp); 
TNF-α (tumor necrosis factor-α), 5’-CATCTTCTCAAAACTCGAGTGACAA-3’ F and 5’-
TGGGAGTAGATAAGGTACAGCCC-3’ R (174 bp); 
IL-6, 5’-TCACAGAAGGAGTGGCTAAGG-3’ F and 5’-GCTTAGGCATAGCACACTAGG-3’ R 
(115 bp); 
Iba1, 5’-AACTGGAGGCCTTCAAGACG-3’ F and 5’-AACCCCAAGTTTCTCCAGCA-3’ R (101 
bp)  
Amounts of each gene product were calculated using linear regression analysis from standard 
curves, demonstrating amplification efficiencies ranging from 90 to 100%. Dissociation curves 
were generated for each primer pair, showing single product amplification. 
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2.3. Aβ peptide toxicity to cortical neurons 
Aβ(1-42) was prepared by dissolving the peptide in 1,1,1,3,3,3-hexafluoro-2-propanol (Sigma) 
to a concentration of 2.5 mg/ml and left at room temperature for 10 min. The 1,1,1,3,3,3-
hexafluoro-2-propanol was then evaporated under a stream of air, and the peptide film was re-
dissolved in dimethylsulfoxide (containing 0.0625% trifluoroacetic acid) to a concentration of 5 
mM. Serum-free medium was pre-warmed to 37°C and added to dilute the 5 mM peptide solution to 
80 µM, before adding to cells to give a final concentration of 20 µM Aβ(1-42) (rat sequence, kindly 
provided by Prof. Vincenzo De Filippis, Scienze del Farmaco).  Aβ(25-35) (Sigma) was prepared as 
a 10 mM stock solution in 0.1% trifluoroacetic acid, and added to the culture medium to achieve the 
indicated final concentrations. 
 
2.4. Immunofluorescence 
Cortical enriched astrocytes or purified spinal cord microglia were seeded on poly-L-lysine-
coated 12-mm diameter coverglasses (Menzel-Gläser, Menzel GmbH, Braunschweig, Germany) 
placed in the wells of a 24 well multiwall plate, at a density of 15,000 or 30,000 cells per well, 
respectively, in culture medium and allowed to adhere overnight. Two days later the cells were 
were fixed with 4% paraformaldehyde for 30 min at 4ºC, and washed 4 x 5 min with PBS/0.05% 
Triton X-100 (PBS-T), and blocked with PBS/10% FCS for 1 h at room temperature. The fixed cell 
monolayers were incubated overnight at 4°C with one of the following primary antibodies: Iba1 
(Wako, rabbit polyclonal affinity purified, 1:500), GFAP (mouse monoclonal, 1:1000, Sigma-
Aldrich, Milan, Italy), P2X7R (rabbit monoclonal, 1:500, Abcam, Cambridge, UK). Cells were then 
washed 5 x 5 min with PBS, and incubated for 1 h at room temperature with anti-mouse-
AlexaFluor555 or anti-rabbit-AlexaFluor488 secondary antibody (1:500, Invitrogen). Nuclei where 
visualized by incubating 2 min with 100 ng/ml 4'-6'-diamidino-2-phenylindole (DAPI) (Boehringer-
Mannheim, Germany). Cover glasses were mounted onto glass slides using Fluoromount-G 
(Southern Biotech, USA), and images were acquired on a Leica DMI4000 B microscope equipped 
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for immunofluorescence (Leica Microsystems GmbH, Wetzlar, Germany) using a Leica DFC 480 
digital camera (Leica Microsystems GmbH, Wetzlar, Germany). 
 
2.5. Mediator release 
Microglia and astrocytes were plated in wells of a 96-well plate (poly-L-lysine coated, or 
collagen for spinal cord astrocytes) at a density of 100,000 or 50,000 cells per well, respectively, 
using glia cell growth medium and allowed to adhere overnight. Cells were stimulated to release 
pro-inflammatory mediators in medium containing the indicated concentration of LPS. In some 
cases cells were pretreated with LPS ('priming') for 2 h in serum-free medium prior to stimulation 
with ATP for 1 h.  
 
2.5.1. Nitric oxide assay 
Nitric oxide (NO) has a relatively short half-life in aqueous solution. Hence, quantitative 
assessment of NO production has generally relied on the indirect measurement of its oxidized 
products, nitrite and nitrate, which are regarded as suitable markers of NO generation. 
Spectrophotometric quantitation of nitrite using Griess Reagent is straightforward, but does not 
measure nitrate. This kit employs the NADH-dependent enzyme nitrate reductase for conversion of 
nitrate to nitrite prior to quantitation of nitrate using Griess reagent — thus providing for accurate 
determination of total NO production. 
 
 
Equal volumes of cell culture medium and Griess reagent (Sigma-Aldrich) were incubated for 15 
min, and the amount of nitrite (as evidenced by the purple azo reaction product) quantified using a 
standard curve of sodium nitrite at O.D. 540 nm. Figure 8 shows a typical standard curve. 
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Figure 8 
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2.5.2. Cytokine ELISA assays 
 
Cells were stimulated to release pro-inflammatory mediators in medium containing the 
indicated concentration of LPS or other agent. Cell supernatants were harvested after 24 hours and 
cytokine release was assayed by sandwich ELISA (Enzyme-Linked Immunosorbent Assay) 
according to the manufacturer’s instructions (Antigenx America, Huntington Station, New York). 
The assay principle is illustrated below: 
 
(1) Plate is coated with a capture antibody; (2) sample is added, and any antigen present binds to 
capture antibody; (3) detecting antibody is added, and binds to antigen; (4) enzyme-linked 
secondary antibody is added, and binds to detecting antibody; (5) substrate is added, and is 
converted by enzyme to detectable form. 
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Figure 9 shows a typical standard curve for IL-1β (similar curves are obtained for TNFα). 
 
Figure 9 
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2.6. Cell vitality assays 
2.6.1. MTT 
This is a colorimetric assay that measures the reduction of yellow 3-(4,5-dimethythiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate dehydrogenase. The MTT 
enters the cells and passes into the mitochondria where it is reduced to an insoluble, coloured (dark 
purple) formazan product. The cells are then solubilized with an organic solvent (e.g. 
dimethylsulfoxide) and the released, solubilized formazan reagent is measured 
spectrophotometrically. Since reduction of MTT can only occur in metabolically active cells the 
level of activity is generally a measure of cell viability (Mosmann, 1983). 
Remove the culture medium from the 96-well plate with a multichannel pipettor. Add to each 
well 50 μL of serum- and phenol red-free DMEM containing 0.15 mg/mL MTT (which represents a 
1:20 dilution from the 3 mg/mL stock in PBS). Incubate the MTT-containing cultures for 1 h at 
37°C. Examination of the cultures under a light microscope will show that viable cells contain blue 
crystals. This is the formazan reaction product. Remove the culture medium by again using the 
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multichannel pipettor and add 50 μL of dimethyl sulfoxide per well. This is to dissolve the reaction 
product. Gently tap the microwell plate from underneath to mix the blue reaction product uniformly 
with the solvent. Read the plate using a SpectraMax M2 microplate reader (Molecular Devices). For 
optimal results, the plate should be read at a wavelength of 570 nm (test wavelength), followed by 
630 nm (reference wavelength). The difference (A570 −A630) is used as the final absorbance value 
generated by the sample. Correcting for optical imperfections in the microplates by subtracting A 
630 is recommended, but is not an essential procedure. 
 
2.6.2. Lactate dehydrogenase (LDH) release assay 
The CytoTox 96® nonradioactive cytotoxicity assay (Promega) measures 
spectrophotometrically the release of LDH into the culture medium, and is an index of loss of 
plasma membrane integrity. The assay was performed following the manufacturer’s instructions, 
and is also detailed in Facci and Skaper (2012b), and will not be repeated here. 
 
2.7. Statistics 
Data are given as mean ± SEM. Statistical analyses to determine group differences were 
performed either by two-sample equal variance Student’s t test, or by one-way analysis of variance, 
followed by Dunnett’s or Bonferroni’s post-hoc tests for comparisons involving more than two data 
groups. 
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3. RESULTS 
 
Part 1 
 
3.1. Cellular, molecular and pharmacological characterization of glia cell Populations from 
cortex, spinal cord and cerebellum, and responsiveness to ATP 
 
3.1.1. Morphological characterization 
Microglia and astrocytes prepared using the methods described here result in cell populations 
which are > 99% and > 95% pure, respectively (Rosin et al., 2004). Immunostaining of cortical 
astrocytes shows a confluent carpet of GFAP+ cells, interspersed with a few Iba1+ immunoreactive 
cells (microglia) (Figure 10, right panels). Purified microglia (spinal cord) show virtually all cells 
labelled for Iba1 (Figure 10, left panels). In these images, nuclei are colored blue with DAPI, which 
forms fluorescent complexes with natural double-stranded DNA.    
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 Figure 10. Immunostaining of purified microglia and enriched astrocytes with the cell-type specific 
markers Iba1 and GFAP, respectively 
                             
 
    Spinal Cord Microglia                                  Cortical Enriched Astrocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
71 
Figure 11. Immunostaining of purified microglia and enriched astrocytes with the cell-type specific 
markers Iba1 and GFAP, respectively 
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3.1.2. Molecular characterization 
Cortical microglia expressed high levels of mRNA for the macrophage/microglia protein Iba1 
(ionized calcium binding adaptor molecule) relative to astrocyte-enriched cultures (Figure 12), 
expressed as a ratio to GFAP. Similar results were obtained for spinal cord microglia (data not 
shown).  
Figure 12. Cortical microglia express high levels of Iba1 mRNA relative to astrocytes 
 
Purified microglia (MO) and enriched astrocyte (AG) cell populations prepared from neonatal rat 
cortex were incubated with the indicated concentrations of LPS for 6 h, and then processed for RT-
PCR analysis. Data, given as means ± SEM (duplicate culture wells) are normalized to GFAP 
levels, and are representative of 3 experiments. Qualitatively similar results were obtained with 
spinal cord microglia and astrocytes. CTR, no-LPS control. 
 
Microglia (Block et al., 2007) and astrocytes (van Noort and Bsibsi, 2009) express toll-like 
receptors (TLRs), a family of pattern-recognition receptors in the innate immune system. TLRs are 
key players in the activation and maintenance of pain and in certain neuropathologies: for example, 
microglial TLR4 has been implicated in oligodendrocyte injury (Lehnardt et al., 2002), 
neurodegeneration (Lehnardt et al., 2003), and apoptosis of activated microglia (Jung et al., 2005), 
while activation of astrocyte-expressed TLRs can lead to the release of pro-inflammatory molecules  
73 
 (van Noort and Bsibsi, 2009) and modulate features of the immune response (Dong and Benveniste, 
2001; Farina et al., 2007). Intracerebral (Lehnardt et al., 2002; Pang et al., 2010) or systemic 
(Lehnardt et al., 2003; Qin et al., 2007) delivery of LPS the major component of Gram-negative 
bacterial walls and a ligand for TLR4, leads to microglia activation and neural cell injury, and is 
used as a model for CNS inflammation (Belarbi et al., 2012; Kellom et al., 2012; Machado et al., 
2011; Qin et al., 2007). 
Indeed, LPS concentration-dependently up-regulated expression of mRNA for iNOS, IL-1β and 
TNF-α in purified cortical microglia and enriched astrocytes (Figure 13) although the relative 
degree of induction and LPS sensitivity appeared to be more robust in microglia. It is interesting to 
note that LPS also up-regulated expression of Iba1 mRNA as well (Figure 12).  
 
Figure 13. LPS induces pro-inflammatory gene expression in cortical microglia and astrocytes 
 
 
 
Purified microglia (MO) and enriched astrocyte (AG) cell populations prepared from neonatal rat 
cortex were incubated with the indicated concentrations of LPS for 6 h, and then processed for RT-
PCR analysis of: iNOS (left panel), IL-1β (mddle panel), and TNF-α (right panel) mRNA. Data are 
means ± SEM (duplicate culture wells) normalized to the housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) levels, and are representative of 3 experiments. 
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 3.1.3. Biochemical characterization 
LPS concentration-dependently up-regulated expression/output of IL-1β protein, as determined 
by ELISA, from both purified cortical microglia and enriched astrocytes (Figure 14). Again, the 
relative degree of induction and LPS sensitivity appeared to be more robust in microglia. Spinal 
cord glia exhibited qualitatively similar behaviors (data not shown). 
 
Figure 14. LPS induces IL-1β production/output from cortical microglia and astrocytes 
 
 
 
 
 
 
 
 
 
 
Purified microglia () and enriched astrocyte () cell populations prepared from neonatal rat 
cortex were seeded in 96 well plates (50,000 and 100,000 cells, respectively), and incubated the 
following day with the indicated concentrations of LPS for 24 h. The IL-1β content of the culture 
medium was determined by sandwich ELISA. Data are means ± SEM (triplicate culture wells). 
 
 
Further, BzATP, but not ATP (the former a more potent P2X7R agonist) (Donnelly-Roberts et al., 
2009) increased (albeit modestly) IL-1β output from cortical microglia over a 48-h period (Figure 
15) – in contrast to the robust response elicited by LPS. In the case of cortical astrocytes only LPS 
treatment led to IL-1β release into the culture medium (Figure 16), and this response was again 
more modest in comparison to that of microglia.  
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Figure 15. BzATP, but not ATP induces IL-1β production/output from cortical microglia 
 
 
 
 
 
 
 
 
 
Purified microglia prepared from neonatal rat cortex were seeded in 96 well plates (100,000 cells), 
and incubated the following day with the indicated concentrations of LPS, ATP, or BzATP for 24 h. 
The IL-1β content of the culture medium was determined by sandwich ELISA. Data are means ± 
SEM (triplicate culture wells). The increase elicited by 1 mM BzATP differed significantly 
(**p<0.01, ***p<0.001) from control values at all time points. 
 
 
 
 
Figure 16. Neither BzATP nor ATP induces IL-1β production/output from cortical astrocytes 
 
Enriched astrocytes prepared from neonatal rat cortex were seeded in 96 well plates (50,000 cells), 
and incubated the following day with the indicated concentrations of LPS, ATP, or BzATP for 24 h. 
The IL-1β content of the culture medium was determined by sandwich ELISA. Data are means ± 
SEM (triplicate culture wells). 
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Biological activity of IL-1 is the result of transcription of two related gene products: IL-1α and 
IL-1β. Both IL-1α and IL-1β are synthesized as 31–34-kDa procytokines and are then converted 
into the mature 17-kDa form; however, although IL-1α is biologically active in both the pro and 
mature form, IL-1β is only active in the mature form (Beuscher et al., 1990). Conversion of pro into 
mature IL-1β is catalyzed by a cysteine protease known as IL-1β-converting enzyme (Dinarello, 
1998) that is the prototypical member of the caspase family (caspase 1) (Thornberry et al., 1992). 
Proteolytical maturation is also linked via a poorly known mechanism to IL-1β release into the 
extracellular space. Likewise, peritoneal macrophages, microglial cells, and dendritic cells respond 
weakly to LPS stimulation, thus suggesting that a second stimulus may be needed to elicit IL-1β 
secretion from these cell types. Endotoxin (LPS)-dependent release of IL-1β from rodent microglial 
cells is a very inefficient process, and secreted IL-1β is mostly in the procytokine unprocessed form. 
Among stimuli reported to enhance and accelerate IL-1β release from mononuclear phagocytes 
(cytolytic T cells, K+ ionophores, bacterial exotoxins, and ATP) (Bhakdi et al., 1990; Hogquist et 
al., 1991b; Perregaux and Gabel, 1994), ATP is one of the most interesting because this nucleotide 
is present at a concentration of 5-10 mM in the cytosol of most cells, thus it can be released in large 
amounts following plasma membrane damage or acute cell death. Furthermore, it is becoming 
increasingly clear that ATP is released by several cell types via nonlytic pathways in response to 
stimulation with many different agonists, among which is LPS itself (Cotrina et al., 1998; Ferrari et 
al., 1998; Sugita et al., 1998). ATP, via activation of P2X7R, is one of the most powerful stimuli 
for secretion of IL-1β in its mature form (Ferrari et al., 1996, 1997c; Hogquist et al., 1991a; 
Perregaux and Gabel, 1994, 1998). Intriguingly, ATP is an efficient stimulus for IL-1β secretion 
only after the cells have undergone a short 'priming' with endotoxin, suggesting that this nucleotide 
is unable to trigger transcription of the IL-1β gene, but rather acts post-translationally, probably 
accelerating the step(s) involved in the proteolytical maturation of this cytokine. 
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To verify this priming behavior, cultures of purified cortical microglia and enriched astrocytes 
were first incubated with different concentrations of LPS for 2 h, followed by addition of 5 mM 
ATP and incubation continued for another 60 minutes. This concentration of ATP was chosen based 
on the earlier studies of Sanz and Di Virgilio (2000). Culture medium was then collected and 
analyzed for IL-1β content (Figure 17). 
 
Figure 17. Addition of extracellular ATP to LPS-primed cortical microglia and astrocytes 
augments the release of IL-1β 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical microglia (panel A) and enriched astrocytes (panel B) were seeded in 96 well 
plates (50,000 and 100,000 cells, respectively), and incubated the following day with the indicated 
concentrations of LPS for 2 h. ATP (5 mM) was then added to the cultures and incubation continued for a 
further 60 minutes. The IL-1β content of the culture medium was determined by sandwich ELISA. Data are 
means ± SEM (triplicate culture wells). 
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The increase in IL-1β release elicited by ATP was concentration-dependent (Figure 18). The 
'background' increase in IL-1β output from cortical microglia and astrocytes exposed to 1 μg/ml 
LPS for 3 h was variable, and ATP (up to 5 mM) on its own produced little or no IL-1β release over 
the time-course of the priming experiment. 
 
Figure 18. Addition of extracellular ATP to LPS-primed cortical microglia and astrocytes augments 
the release of IL-1β 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical microglia (left panel) and enriched astrocytes (right panel) were seeded in 96 
well plates (50,000 and 100,000 cells, respectively), and incubated the following day with 1 μg/ml LPS for 2 
h. ATP (5 mM) was then added to the cultures and incubation continued for a further 60 minutes. The IL-1β 
content of the culture medium was determined by sandwich ELISA. Data are means ± SEM (triplicate 
culture wells). *p<0.05 and ***p<0.001 vs LPS alone. 
 
 
Addition of extracellular ATP to LPS-primed spinal cord microglia also produced a robust release 
of IL-1β (Figure 19), and in spinal cord astrocytes (to be described later). The priming response 
was found to occur as well in cerebellar-derived microglia and astrocytes (Figure 20). The latter 
observations are novel, in that priming has not been reported previously for glia of either spinal 
cord or cerebellar origin. 
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Figure 19. Addition of extracellular ATP to LPS-primed spinal cord microglia augments the 
release of IL-1β 
 
 
 
 
 
 
 
 
 
Purified neonatal rat spinal cord microglia were seeded in 96 well plates (100,000), and incubated the 
following day with 1 μg/ml LPS for 2 h. ATP (5 mM) was then added to the cultures and incubation 
continued for a further 60 minutes. The IL-1β content of the culture medium was determined by sandwich 
ELISA. Data are means ± SEM (triplicate culture wells). 
 
 
 
Figure 20. Addition of extracellular ATP to LPS-primed cerebellar microglia and astrocytes 
augments the release of IL-1β 
 
 
 
 
 
 
 
 
 
 
 
Purified microglia (left panel) and enriched astrocytes (right panel) cultured from 7-day postnatal rat 
cerebellum were seeded in 96 well plates (50,000 and 100,000 cells, respectively), and incubated the 
following day with 1 μg/ml LPS for 2 h. ATP (5 mM) was then added to the cultures and incubation 
continued for a further 60 minutes. The IL-1β content of the culture medium was determined by sandwich 
ELISA. Data are means ± SEM (triplicate culture wells). 
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3.1.4. Pharmacological characterization 
In order to confirm the involvement of P2X7R in the ATP-dependent augmentation of IL-1β 
release from LPS-primed cells, the above experiments were repeated in the presence of a series of 
P2X7R antagonists differing in chemical structure and target affinity. A-740003 is a potent (pIC50 
7.0 for rat) and selective P2X7R antagonist (Honore et al., 2006) (Figure 21):  
 
Figure 21. A-740003 is a highly selective P2X7 antagonist 
 
 
 
 
A-740003 selectively blocks P2X7 receptors and not other P2 subtypes. ATP (4 μM) was used to activate 
P2X1, P2X4, and P2Y1 receptors, and ATP (10 μM) was used for P2X2a and P2X2a/3 receptors. UTP (1 μM) 
was used to activate P2Y2 receptors. BzATP (5 μM) was used for human P2X7 receptors. (Taken from 
Honore et al. J. Pharmacol. Exp. Ther. 2006) 
 
 
A-740003 (10 µM) completely abolished IL-1β release which occurred over and above that 
obtained with LPS (1 µg/ml) alone, in both cortical purified microglia and enriched astrocytes 
(Figure 22, left and right panels, respectively).   
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Figure 22. The P2X7R antagonist A-740003 blocks the rise in IL-1β release caused by addition of 
extracellular ATP to LPS-primed cortical microglia and astrocytes 
 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical microglia (left panel) and enriched astrocytes (right panel) were seeded in 96 
well plates (50,000 and 100,000 cells, respectively), and incubated the following day with: A-740003 (10 
µM) for 30 minutes, followed by additional of 1 μg/ml LPS for 2 h. ATP (5 mM) was then added to the 
cultures, where indicated, and incubation continued for a further 60 minutes. The IL-1β content of the culture 
medium was determined by sandwich ELISA. Data are means ± SEM (triplicate culture wells). 
 
 
A concentration-response comparison of A-740003 with another P2X7R antagonist, Brilliant Blue 
G (pIC50 6.0 for rat) (Donnelly-Roberts et al., 2009) showed that these two compounds blocked the 
ATP-dependent component of IL-1β release from LPS-primed cortical astrocytes in keeping with 
their reported target affinities (Figure 23). The structurally unrelated, potent and selective P2X7R 
antagonist AZ10606120 (pIC50 6.5 for rat) (Michel et al., 2008) which binds in a positive 
cooperative manner to sites distinct from, but coupled to, the ATP binding site also abolished the 
ATP-dependent component of IL-1β release from LPS-primed cortical astrocytes (Figure 24), as 
did the competitive P2X7R antagonist A-438079 (Nelson et al., 2006) and the irreversible 
antagonist periodate-oxidized ATP (ATP-P) (pIC50  ~4.5) (Figure 25).  
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Figure 23. The P2X7R antagonists A-740003 and Brilliant Blue G concentration-dependently 
block the rise in IL-1β release caused by addition of extracellular ATP to LPS-primed cortical 
astrocytes 
 
 
 
 
 
 
 
 
 
Rat cortical enriched astrocytes were seeded in 96 well plates (50,000 cells), and incubated the following day 
with: A-740003 or Brilliant Blue G at the concentrations indicated for 30 minutes, followed by additional of 
1 μg/ml LPS for 2 h. ATP (5 mM) was then added to the cultures and incubation continued for a further 60 
minutes. The IL-1β content of the culture medium was determined by sandwich ELISA. Data are means ± 
SEM (triplicate culture wells). 
 
 
 
Figure 24. The P2X7R antagonist AZ10606120 concentration-dependently blocks the rise in IL-1β 
release caused by addition of extracellular ATP to LPS-primed cortical astrocytes 
 
 
 
 
 
 
 
 
 
 
Rat cortical enriched astrocytes were seeded in 96 well plates (50,000 cells), and incubated the following day 
with: AZ10606120 at the concentrations indicated for 30 minutes, followed by additional of 1 μg/ml LPS for 
2 h. ATP (5 mM) was then added to the cultures and incubation continued for a further 60 minutes. The IL-
1β content of the culture medium was determined by sandwich ELISA. Data are means ± SEM (triplicate 
culture wells). 
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Figure 25. The P2X7R antagonists A-438079 and periodate-oxidized ATP (ATP-P) concentration-
dependently block the rise in IL-1β release caused by addition of extracellular ATP to LPS-primed cortical 
astrocytes. 
 
Rat cortical enriched astrocytes were seeded in 96 well plates (50,000 cells), and incubated the following day 
with: A-438079 or ATP-P at the concentrations indicated for 30 minutes, followed by additional of 1 μg/ml 
LPS for 2 h. ATP (5 mM) was then added to the cultures and incubation continued for a further 60 minutes. 
The IL-1β content of the culture medium was determined by sandwich ELISA. Data are means ± SEM 
(triplicate culture wells). 
 
 
In the dorsal horn of spinal cord, pharmacological inhibition of P2X7R with A-438079 prevents 
LPS-induced release of IL-1β; cytokine release is also absent in spinal cord slices taken from 
P2X7R knock-out mice (Clark et al., 2010). Application of ATP did not evoke release of IL-1β 
from the dorsal horn unless preceded by an LPS priming stimulus, and this release was dependent 
on P2X7R activation. Extensive phosphorylation of p38 MAPK in microglial cells in the dorsal 
horn was found to correlate with IL-1β secretion following both LPS and ATP. When cortical and 
spinal cord microglia were pretreated for 30 minutes with the selective p38 inhibitor SB-202190, 
IL-1β output from ATP-challenged and LPS-primed was reduced (Figure 26). Similar results were 
obtained with a second, structurally different p38 inhibitor (SB-239063) (not shown).   
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Figure 26. The p38 MAPK inhibitor SB-202190 reduces the rise in IL-1β release caused by addition of 
extracellular ATP to LPS-primed cortical and spinal cord microglia 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical (left panel) and spinal cord (right panel) microglia were seeded in 96 well plates 
(100,000 cells), and incubated the following day with: SB-202190 (10 µM) for 30 minutes, followed by 
additional of 1 μg/ml LPS for 2 h. ATP (5 mM) was then added to the cultures, where indicated, and 
incubation continued for a further 60 minutes. The IL-1β content of the culture medium was determined by 
sandwich ELISA. Data are means ± SEM (triplicate culture wells). ***p<0.001 vs LPS+ATP. 
 
 
Unexpectedly, the p38 MAPK inhibitor SB-202190 caused a marked increase in IL-1β release from 
both cortical and spinal cord microglia incubated with LPS for 24 h (Figure 27). However, SB-
202190 augmented IL-1β release from these long-term LPS-treated cortical and spinal cord 
microglia in a manner that was influenced by the concentration of FBS in the culture medium 
(Figure 28). The reason for the effect of FBS on this behavior is not known, but may account for 
the lack of increase in IL-1β in p38-treated microglia subjected to a priming stimulus (Figure 26). 
This effect of the p38 inhibitor was not general, as neither the LPS-stimulated rise in IL-6 nor NO 
release was augmented; SB-202190 actually decreased NO production (Figure 29). Noradrenaline, 
which has been reported to inhibit IL-1β and NO release from LPS-stimulated microglia (Dello 
Russo et al., 2004), did so in both spinal cord (Figure 30) and cortical (not shown) microglia. 
However, noradrenaline did not affect IL-1β release in the priming response (see Part 3). 
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Figure 27. The p38 MAPK inhibitor SB-202190 strongly increases IL-1β release from long-term LPS-
treated cortical microglia and astrocytes 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical (left panel) and spinal cord (right panel) microglia were seeded in 96 well plates 
(100,000 cells), and incubated the following day with: SB-202190 (10 µM) for 30 minutes, followed by 
addition of 10 ng/ml LPS for 24 h. The IL-1β content of the culture medium was then determined by 
sandwich ELISA. Data are means ± SEM (triplicate culture wells). ***p<0.001 vs LPS alone. 
 
 
Figure 28. The p38 MAPK inhibitor SB-202190 augments IL-1β release from long-term LPS-treated 
cortical and spinal cord microglia: influence of FBS concentration. 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical (left panel) and spinal cord (right panel) microglia were seeded in 96 well plates 
(100,000 cells), and incubated the following day with: SB-202190 (10 µM) for 30 minutes, followed by 
addition of 10 ng/ml LPS for 24 h. The IL-1β content of the culture medium was then determined by 
sandwich ELISA. Data are means ± SEM (triplicate culture wells). *p<0.05, **p<0.01 and ***p<0.001 vs 
the corresponding LPS-only cultures at that concentration of FBS. 
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Figure 29. The p38 MAPK inhibitor SB-202190 augments IL-1β release, but not IL-6 or NO, from long-
term LPS-treated spinal cord microglia 
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Purified neonatal rat spinal cord microglia were seeded in 96 well plates (100,000 cells), and incubated the 
following day with: SB-202190 (10 µM) for 30 minutes, followed by addition of 10 ng/ml LPS for 24 h. The 
IL-1β, IL-6 and NO contents of the culture medium were then determined as described under Methods. 
 
 
Figure 30. Norepinephrine inhibits IL-1β and NO release from spinal cord microglia treated 24 h with LPS 
 
 
 
 
 
 
 
 
Purified neonatal rat spinal cord microglia were seeded in 96 well plates (100,000 cells), and incubated the 
following day with: the indicated concentrations of norepinephrine for 30 minutes, followed by addition of 
10 ng/ml LPS for 24 h. The IL-1β and NO contents of the culture medium were then determined as described 
under Methods. 
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Part 2 
 
3.2. The role of astrocytes in the P2X7R priming response with ATP 
 
As demonstrated in Part 1 (Figure 22) not only microglia, but also astrocytes appear to release 
IL-1β  following addition of extracellular ATP to LPS-primed cells. Astrocytes are the predominant 
cell type in the CNS; hence, confirming their ability to display P2X7R-dependent release of the pro-
inflammatory cytokine IL-1β  is an important question. The elucidation of astrocyte function has 
benefited from the ability to study these glial cells under defined conditions in vitro. Although 
astrocyte cultures are relatively easy to establish, these cultures can be contaminated by microglia, 
which have been shown to modify astrocyte responses under certain circumstances (Brown et al., 
Ciccarelli et al., 2000; Xiong et al., 1999). Furthermore, because pro-inflammatory stimuli can 
affect the expression of similar genes in microglia and astrocytes, interpretation of results using 
astrocyte cultures can be confounded by the presence of contaminating microglia (Saura et al., 
2003; Solà et al., 2002). Anti-mitotic agents have been employed to inhibit microglial growth in 
primary astrocyte cultures (Hewett, 1999; Swanson et al., 1997). However, such an approach can be 
applied only on high-density monolayers after the astrocytes have entered a non-proliferative state 
induced by cell–cell contact. This allows a period of microglial cell growth prior to mitotic 
inhibition; thus, such cultures can still have a considerable number of microglia present. 
L-leucyl-L-leucine methyl ester (L-LME) (Figure 31) is a lysosomotropic agent originally used 
to selectively destroy macrophages (Thiele et al., 1983). It was later found that brief incubation with 
L-LME in general eliminates cells with cytotoxic potential (for example, cytotoxic T cells, natural 
killer cells), and has been employed to deplete microglia from neural cultures including astrocytes 
(Giulian et al., 1993; Guillemin et al., 1997) and oligodendrocytes (Hewett et al., 1999). L-LME-
mediated toxicity is dependent on the conversion of membranolytic products of structure (Leu-
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Leu)n-OMe (n>3) by the acyltransferase activity of the enzyme dipeptidyl peptidase I, a lysosomal 
thiol protease also known as cathepsin C (Thiele and Lipsky, 1990).  
 
Figure 31 
 
 
Hamby et al. (2006) recently demonstrated that exposing confluent cortical astrocytes to 50-75 mM 
L-LME for 60-90 minutes effectively depleted microglia from the high-density astrocyte 
monolayers, as evidenced by the selective depletion of microglial-specific markers. Purified 
monolayers appeared morphologically normal 24 h after L-LME treatment and expressed iNOS and 
cyclooxygenase-2 proteins upon stimulation with LPS plus IFN-γ, albeit (and not surprisingly) to a 
lower level than unpurified monolayers. L-LME treatment did not alter global protein synthesis and 
a reactive phenotype could be induced in the purified monolayers upon treatment with cyclic AMP-
elevating agents. 
To verify the effect of L-LME treatment in our cultures enriched cortical and spinal cord 
astrocytes were first incubated 60 minutes with 50 mM L-LME, and then stimulated 48 h later with 
LPS for 6 h and processed for Iba-1 gene expression by RT-PCR. In addition, and to control for a 
microglia-specific expression of the Iba-1 signal, some cultures received varying numbers of 
purified microglia 24 h after L-LME. The latter were left for 24 h to allow microglia to attached, 
and were then treated with LPS for 6 h. As Figure 32 shows, L-LME treatment effectively 
eliminated Iba-1 mRNA expression from both cortical and spinal cord astrocytes. Further, the re-
addition of purified microglia to L-LME-treated astrocytes resulted in the reappearance of Iba-1 
gene expression, as a function of microglia cell number introduced.  
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Figure 32. L-LME treatment of cortical and spinal cord astrocytes eliminates Iba1 gene expression: effect of 
microglia addition 
 
 
Enriched astrocyte cell populations prepared from either tissue were treated for 60 minutes with 50 mM L-
LME, and returned to fresh culture medium for 24 h. After this time purified cortical or spinal cord microglia 
were added to the astrocyte cultures, at the densities indicated, and incubation continued for a further 24 h. 
Cultures were then challenged with LPS (10 ng/ml) and processed for Iba1 mRNA expression by RT-PCR 
after 6 h. Data are means ± SEM (duplicate culture wells) normalized to GAPDH levels, and are 
representative of 3 experiments. 
 
The reintroduction of purified microglia to L-LME-treated astrocytes resulted in the recovery of 
functional LPS responsiveness, as well. An example of this is shown in Figure 33. Under these 
conditions L-LME (first three sets of columns from the left in each figure): eliminated the LPS 
induction of IL-1β mRNA in cortical and spinal cord astrocytes (Panel A); reduced, but did not 
fully abolish the LPS-induced rise in IL-6 (Panel B) and TNF-α (Panel C) mRNA; abolished in 
spinal cord, but did not cortical astrocytes the LPS-induced rise in iNOS mRNA expression (Panel 
D). This last observation is consistent with the reported expression by rodent cortical astrocytes of 
iNOS in vitro (Akama et al., 2000; Buskila et al., 2005) even after treatment with L-LME (Hamby 
et al., 2006) and in vivo (Murphy, 2000). A lower L-LME concentration (5mM) was ineffective 
while incubating purified microglia with 50 mM (but not 5 mM) L-LME for 60 minutes resulted in 
complete cell destruction after 24 h, assessed morphologically and with the MTT vitality assay. 
Astrocytes treated with 50 mM L-LME did not evidence any overt morphological changes or loss of 
MTT reactivity or GFAP immunostaining (data not shown). 
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Figure 33. L-LME treatment of cortical and spinal cord astrocytes limits pro-inflammatory gene induction 
by LPS: effect of microglia addition 
 
Enriched astrocyte cell populations prepared from either tissue were treated for 60 minutes with 50 mM L-
LME, and returned to fresh culture medium for 24 h. After this time the indicated numbers of purified 
cortical or spinal cord microglia were added to the astrocyte cultures, and incubation continued for a further 
24 h. Cultures were then challenged with LPS (10 ng/ml) and processed for mRNA expression by RT-PCR 
after 6 h: IL-1β (panel A), IL-6 (panel B), TNF-α (panel C), iNOS (panel D).  Data are means ± SEM 
(duplicate culture wells) normalized to GAPDH levels, and are representative of 3 experiments. Culture 
wells seeded with the same numbers of microglia contained too little material to reliably process. 
 
Reintroduction of microglia (second three sets of columns in each panel) restored LPS 
responsiveness for IL-1β (Figure 33A) and IL-6 (Figure 33B) release; the effect was more 
pronounced in spinal cord glia co-cultures. In the latter, expression levels clearly exceeded those for 
L-LME-treated astrocytes already at the lowest microglia number (9,000), and approached values of 
LPS-stimulated (but L-LME untreated) astrocytes with 36,000 microglia. For TNF-α, microglia 
addition to L-LME-depleted astrocytes also restored LPS responsiveness, but in this case cortical-
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derived glia appeared more sensitive to the presence of microglia in comparison to spinal cord 
(Figure 33C). Addition of spinal cord microglia to L-LME-treated astrocytes fully restored iNOS 
gene induction by LPS, becoming evident already with the lowest number of microglia added 
(Figure 33D). The effect of microglia addition was less evident for cortical astrocytes, as iNOS 
mRNA expression remained relatively high even after treatment with L-LME. 
The ability to reconstitute LPS responsiveness in microglia/astrocyte co-cultures was also 
observed in terms of mediator output. Addition of microglia to L-LME-treated cortical astrocytes 
resulted in NO release in relation to the number of microglia added, becoming already detectable 
with less than 1000 cells per culture well (Figure 34, left panel). In contrast, the same numbers of 
microglia, in the absence of astrocytes failed to produce NO upon incubation with LPS, except at 
the highest number (Figure 34, right panel). A similar behaviour was observed in the case of IL-6 
(not shown). 
 
Figure 34. Co-culture of cortical microglia and L-LME-treated cortical astrocytes restores LPS-induced NO 
release 
 
Left panel: Enriched cortical astrocytes cultured in a 96 well microplate were treated with 50 mM L-LME for 
60 minutes, and returned to fresh culture medium for 24 h. After this time purified cortical microglia were 
added, at the numbers indicated, to the astrocyte cultures and incubation continued for a further 24 h. 
Cultures were then challenged with LPS (10 ng/ml) and the culture medium collected after 24 h for analysis 
of NO content. 
Right panel: The same numbers of microglia were cultured in a parallel plate, treated with LPS as above and 
medium analyzed for NO content. Data are means ± SEM (n=3). Cultures derived from spinal cord microglia 
and astrocytes behaved in a qualitatively similar fashion (not shown). 
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Addition of cortical microglia to L-LME-treated cortical astrocytes restored the priming 
response to LPS (IL-β release), an effect proportionate to the numbers of microglia (Figure 35, left 
panel). As for the case of NO release in LPS-stimulated astrocyte-mocroglia co-cultures, equivalent 
numbers of purified microglia cultured in the absence of astrocytes failed to generate appreciable 
amounts of IL-β when incubated with LPS, except at the highest cell number (Figure 35, right 
panel). Qualitatively similar results were obtained using cerebellar-derived astrocytes and microglia 
(Figure 36).  
 
Figure 35. Co-culture of cortical microglia and L-LME-treated cortical astrocytes restores LPS sensitization 
to ATP-induced release of IL-1β 
 
 
Left panel: Enriched cortical astrocytes cultured in a 96 well plate were treated with 50 mM L-LME for 60 
minutes, and returned to fresh culture medium for 24 h. After this time purified cortical microglia were 
added, at the numbers indicated, to the astrocyte cultures and incubation continued for a further 24 h. The 
cultures were then incubated in serum-free medium with 1 µg/ml LPS for 2 h followed by addition of ATP to 
a final concentration of 5 mM. After a further 60 minutes incubation culture medium was collected for IL-1β 
analysis. 
Right panel: The same numbers of microglia were cultured in a parallel plate, treated with LPS and ATP as 
above and medium analyzed for IL-1β content.  Data are means ± SEM (n=3). Cultures derived from spinal 
cord microglia and astrocytes behaved in a qualitatively similar fashion (not shown). 
 
 
 
 
 
93 
Figure 36. Co-culture of cerebellar microglia and L-LME-treated cerebellar astrocytes restores LPS 
sensitization to ATP-induced release of IL-1β 
 
 
 
 
 
 
 
 
 
 
 
Left panel: Enriched cerebellar astrocytes cultured in a 96 well plate were treated with 50 mM L-LME for 60 
minutes, and returned to fresh culture medium for 24 h. After this time purified cerebellar microglia were 
added, at the numbers indicated, to the astrocyte cultures and incubation continued for a further 24 h. The 
cultures were then incubated in serum-free medium with 1 µg/ml LPS for 2 h followed by addition of ATP to 
a final concentration of 5 mM. After a further 60 minutes incubation culture medium was collected for IL-1β 
analysis. 
Right panel: The same numbers of microglia were cultured in a parallel plate, treated with LPS and ATP as 
above and medium analyzed for IL-1β content.  Data are means ± SEM (n=3). 
 
 
The increased release of mediators in microglia-astrocyte co-cultures could be due to soluble factors 
derived from microglia. For example, IL-1β can activate astrocytes (Guo et al., 2004; Wu et al., 
2008) and increase their production of NO (Chao et al., 1996). However, addition of IL-1β to 
microglia-depleted astrocytes, up to amounts produced by the equivalent of 100,000 microglia in a 
96-well culture, failed to cause release of NO (unpublished observations). This question was next 
addressed by examining the effect of conditioned medium from L-LME-treated and LPS-stimulated 
astrocytes on mediator output from purified microglia. The experimental design was similar to that 
in Figure 33, except that parallel sets of cultures with a range of microglia numbers received either 
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LPS or medium conditioned over astrocytes incubated with LPS for 24 h. Cortical astrocytes treated 
with L-LME, as expected, failed to produce NO upon incubation with LPS (10 ng/ml) (Figure 
37A). Addition of cortical microglia to L-LME-treated astrocytes, followed by stimulation with 
LPS resulted in the recovery of LPS responsiveness in a microglia cell number-dependent manner. 
Again, and consistent with Figure 34, the same numbers of microglia alone (625 – 20,000) gave 
little or no signal upon LPS exposure for 24 h (Figure 37B). When a parallel plate of microglia was 
incubated with medium from astrocytes treated with LPS (10 ng/ml) for 24 h, NO release levels 
were very low and well below values achieved for astrocyte-microglia co-cultures (Figure 37C). A 
similar experiment was not carried out for the priming response, as the relatively short (2 h) 
incubation time with LPS prior to ATP addition is unlikely to have resulted in the de novo synthesis 
of mediator(s). 
 
Figure 37: A-B-C. Culture medium from microglia-depleted, LPS-treated cortical astrocytes is not 
sufficient to provoke NO release from microglia alone. 
Panel A: Enriched cortical astrocytes cultured in 96 well microplates were treated with 50 mM L-
LME for 60 min, and returned to fresh culture medium for 24 h. After this time purified cortical 
microglia were added to one plate of astrocytes, at the numbers indicated, and incubation continued 
for a further 24 h. Cultures were then challenged with LPS (10 ng/ml) and the culture medium 
collected after 24 h for analysis of NO content. The far right column (100,000 microglia) did not 
receive LPS. In this experiment culture wells seeded with 100,000 microglia were included as a 
'reference point', as this is the density normally used in our 96 well format. The second plate of 
LPS-treated astrocytes (no microglia added) was used to generate conditioned medium (see panel 
C).  
Panel B: The same numbers of microglia as in panel A were cultured alone in a parallel plate, 
treated with LPS as above and medium analyzed for NO content after 24 h. 
Panel C: A second plate of microglia (same numbers as in panel B) received conditioned medium 
from the LPS-treated astrocytes (see panel A). NO release was analyzed after 24 h. All data are 
means ± SEM (n=3). 
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Figure 37: A-B-C. Culture medium from microglia-depleted, LPS-treated cortical astrocytes is not 
sufficient to provoke NO release from microglia alone. 
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 Part 3 
 
3.3. Is the P2X7R priming response strictly dependent on ATP, LPS and TLR4? 
 
3.3.1. Amyloid peptide 
As discussed above, extracellular ATP is a mediator of intercellular communication and a 
danger signal. Release of this and other nucleotides modulates microglia responses via P2Y and 
P2X receptors, among which the P2X7 subtype stands out for its pro-inflammatory activity. For 
example, increased expression of P2X7R mRNA has been described in AD-derived microglia 
compared to non-demented brain, along with prominent P2X7R protein immunoreactivity in 
association with Aβ plaques and localized to HLA-DR-immunoreactive microglia (McLarnon et al., 
2006) as well as in a mouse model of AD (Parvathenani et al., 2003). Despite unequivocal evidence 
for Aβ-mediated activation of microglia, the plasma membrane receptors involved are largely 
unknown. Different receptors, among which CD36 (El Khoury et al., 1996), α6β1 integrins, CD14, 
the formyl peptide receptor-like protein, and TLR2 (Chen et al., 2006) are ligated by Aβ, thus 
leading to microglia activation, generation of inflammatory mediators and Aβ internalization. Sanz 
et al. (2009) reported that the Aβ fragment (25-35) triggered increases IL-1β secretion in LPS-
primed microglia from wild-type but not from P2X7R-deleted mice. However, the Aβ(25-35) 
fragment does not occur in nature; rather, Aβ(1-42) is the peptide that is initially deposited within 
the extracellular plaques of AD patients and is highly prone to aggregation. Soluble oligomers of 
Aβ(1-42) are now believed to be the principal pathological form and are synaptotoxic (Lacor et al., 
2007). 
To examine further the ability of Aβ to trigger IL-1β release from LPS-primed purified 
microglia and enriched astrocytes, these two glial cell populations were first incubated with 1 µg/ml 
LPS for 2 h, followed by addition of either Aβ(25-35) or Aβ(1-42) (20 µM), or 5 mM ATP. As 
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Figure 38 shows, neither Aβ peptide was able to provoke IL-1β release, while ATP functioned as 
expected. The action of ATP was blocked by 10 µM A740003. 
 
Figure 38. Aβ peptides are unable to mimic the effect of ATP in enhancing IL-1β release from 
LPS-primed cortical microglia  
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical microglia were seeded in 96 well plates (100,000 cells), and incubated the 
following day with: A740003 (10 µM) where indicated for 30 minutes, followed by addition of 1 μg/ml LPS 
for 2 h. ATP (5 mM), Aβ(25-35) (20 µM) or Aβ(1-42) (20 µM)was then added to the cultures, as 
indicated, and incubation continued for a further 60 minutes. The IL-1β content of the culture medium was 
determined by sandwich ELISA. Data are means ± SEM (triplicate culture wells). 
 
3.3.2. Ethanol intoxication 
The brain is one of the major target organs of ethanol actions, and its chronic and acute 
intoxication results in significant alterations in brain structure and function, and in some cases to 
neurodegeneration. Ethanol has immunomodulatory effects and induces specific alterations in the 
TLRs response in many tissues. These actions depend on the cell type, ethanol dose and treatment 
duration, as well as the concomitant presence of pathogens and their characteristics. Recent findings 
indicate that low concentrations of ethanol (10 mM) promote inflammatory processes in brain and 
in glial cells by up-regulating cytokines and inflammatory mediators (iNOS, NO, COX-2), and by 
activating signaling pathways (MAPKs) and transcriptional factors (NF-κB) implicated in 
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inflammatory injury (Blanco and Guerri, 2007). TLR4/IL-1RI receptors may be involved in 
ethanol-mediated inflammatory signaling, since pharmacologically blocking or genetic deletion 
these receptors abolishes the production of ethanol-induced inflammatory mediators and cell death 
(Blanco and Guerri, 2007; Fernandez-Lizarbe et al., 2009). In summary, these studies suggest that 
TLR4/ IL-1RI are important targets of ethanol-induced inflammatory brain damage. 
To investigate the possibility that ethanol could activate microglia and replace LPS in the 
priming response to ATP, spinal cord microglia were first incubated with 10-100 mM ethanol for 24 
and 48 h (following the conditions described by Fernandez-Lizarbe et al. (2009). While LPS (50 
ng/ml) incubation resulted in the expected production of NO, none of the ethanol concentrations 
tested were effective (Figure 39). The TLR4 antagonist polymyxin B (10 µg/ml) fully blocked the 
activity of LPS. The measurement of NO was chosen, as its release was the most robust response to 
ethanol (equivalent to LPS) as reported by Fernandez-Lizarbe et al. (2009). Comparable results 
were obtained using cortical microglia (not shown).  
 
Figure 39. Ethanol does not stimulate NO production from spinal cord microglia 
 
 
 
 
 
 
 
 
Purified neonatal rat spinal cord were seeded in 96 well plates (100,000 cells), and incubated the following 
day with: 50 ng/ml LPS, or 10-30-100 mM ethanol (EtOH) for 24 h and 48 h, after which time the culture 
medium collected for analysis of NO content. Data are means ± SEM (triplicate culture wells). 
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Cortical and spinal cord microglia were then incubated with 100 mM ethanol or 1 µg/ml LPS for 2 
h, followed by challenge with 5 mM ATP for 1 h. Measurement of IL-1β release into the culture 
medium revealed the expected priming effect of LPS, while ATP was ineffective in ethanol 'primed' 
cells (Figure 40). Interestingly, adenosine 5′-(β,γ-imido)triphosphate (AMP-PNP), a non-
hydrolyzable ATP analog which competitively inhibits ATP-dependent enzyme systems was also 
efficacious in the priming response (Figure 40). 
 
Figure 40. Ethanol cannot stimulate IL-1β release from LPS-primed microglia  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical (upper panel) and spinal cord (lower panel) microglia were seeded in 96 well 
plates (100,000 cells), and incubated the following day with 1 μg/ml LPS for 2 h. ATP (5 mM), EtOH (100 
mM) or AMP-PNP (5 mM) was then added to the cultures as indicated, and incubation continued for a 
further 60 minutes. The IL-1β content of the culture medium was determined by sandwich ELISA. Data are 
means ± SEM (triplicate culture wells). **p<0.01 vs LPS. 
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3.3.3. TLR2 and TLR3 
Focus has recently shifted to TLR signaling pathways in neurodegenerative disorders 
(Campbell, 2004; Jin et al., 2008; Okun et al., 2009), including motor neuron disease (Casula et al., 
2011), brain injury (Campbell, 2004) and neuropathic pain (Christianson et al., 2011). While the 
TLRs were originally described according to their ability to respond to exogenous microbial 
products there is sufficient literature to suggest endogenous products activating TLRs during sterile 
inflammation. In addition to TLR4, microglia also express functional TLR2 (Kim et al., 2007; Shi 
et al., 2011) and TLR3 (Obata et al., 2008; Mei et al., 2011) whose activation participates in nerve 
injury-induced neuropathic pain. However, it is not known if agonists for TLR2 or TLR3 are able to 
prime microglia for ATP-dependent IL-1β release. 
To investigate this question, the response of microglia to TLR2 and TLR3 agonists was 
examined. Zymosan is a desiccated preparation of yeast cell wall commonly employed to stimulate 
the activity of the reactive oxygen species-producing enzyme NADPH oxidase in immune cells 
(DeChatelet et al., 1975), and also activates microglia (Harrigan et al., 2008) by direct binding to 
TLR2 resulting in NF-κB activation and TNF-α secretion (Sato et al., 2003). To first test microglia 
responsiveness to zymosan (Sigma), cells were incubated with different concentrations for 24 h and 
release IL-1β analyzed. As Figure 41 shows, zymosan concentration-dependently stimulated the 
release of IL-1β from both cortical and spinal cord microglia. A concentration of 3 µg/ml zymosan 
was chosen for the remaining experiments.  
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Figure 41. Zymosan concentration-dependently stimulates release from cortical and spinal cord 
microglia 
  
 
 
 
 
 
 
 
 
Purified neonatal rat cortical (left panel) and spinal cord (right panel) microglia were seeded in 96 well plates 
(100,000 cells), and incubated the following day with 10 ng/ml LPS or the indicated concentrations of 
zymosan ('Zy') for 24 h. The IL-1β content of the culture medium was determined by sandwich ELISA. Data 
are means ± SEM (triplicate culture wells). ***p<0.001 vs LPS. 
 
 
Next, microglia were incubated for 2 h with 3 µg/ml zymosan or 1 µg/ml LPS, followed by a 
further incubation with 5 mM ATP for 1 h. Under these conditions, zymosan proved to be 
efficacious as LPS in augmenting IL-1β release (Figure 42). 
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Figure 42. Zymosan is effective like LPS in priming cortical and spinal cord microglia to ATP-
dependent IL-1β release  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat cortical (upper panel) and spinal cord (lower panel) microglia were seeded in 96 well 
plates (100,000 cells), and incubated the following day with 1 μg/ml LPS or 3 µg/ml zymosan for 2 h. ATP 
(5 mM) was then added to the cultures as indicated, and incubation continued for a further 60 minutes. The 
IL-1β content of the culture medium was determined by sandwich ELISA. Data are means ± SEM (triplicate 
culture wells). ***p<0.001 vs LPS. 
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TLR3 is a key pattern recognition receptor for double-stranded RNA and the synthetic double-
stranded RNA poly inosinic:polycytidylic acid (poly I:C) (Alexopoulou et al., 2001), both of which 
potently induce the type I interferons α and β and other inflammatory cytokines (Jacobs and 
Langland, 1996; Matsumoto and Seya, 2008). Microglia recognize double-stranded RNA via TLR3 
(Town et al., 2006). A 2-h incubation of spinal cord microglia to poly(I:C) (Sigma) primed the cells 
to ATP augmentation of IL-1β release, although the effect did not appear to be as robust as with 
LPS or zymosan (Figure 43). 
 
Figure 43. Poly(I:C) is capable of priming spinal cord microglia to ATP-dependent IL-1β release  
 
 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat spinal cord microglia were seeded in 96 well plates (100,000 cells), and incubated the 
following day for 2 h with: 1 μg/ml LPS; 3 µg/ml zymosan; 0.5-50 µg/ml poly(I:C) ('P'). ATP (5 mM) was 
then added to the cultures as indicated, and incubation continued for a further 60 minutes. The IL-1β content 
of the culture medium was determined by sandwich ELISA. Data are means ± SEM (triplicate culture wells). 
*p<0.05 or ***p<0.001 vs the same concentration of poly(I:C) alone. 
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As reported in Part 1, the p38 MAPK inhibitor SB-202190 markedly raised IL-1β release from 
cells incubated with LPS for 24 h (Figure 27), while norepinephrine reduced IL-1β release (Figure 
30). SB-202190 and norepinephrine showed similar behaviors also for zymosan and poly(I:C) 
stimulated spinal cord microglia (Figure 44, compare panel A with panels B and C)).  
 
Figure 44. The p38 MAPK inhibitor SB-202190 markedly elevates IL-1β release from LPS-, zymosan- and 
poly(I:C)-treated spinal cord microglia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat spinal cord microglia were seeded in 96 well plates (100,000 cells), and incubated the 
following day with: 10 µM SB-202190 ('SB') or 10 µM norepinephrine ('NE') for 30 minutes, followed by 
addition of: (A) 10 ng/ml LPS, (B) 3 µg/ml zymosan ('Zy'), (C) 50 µg/ml poly(I:C) for 24 h. The IL-1β 
content of the culture medium was then determined by ELISA. Data are means ± SEM (triplicate culture 
wells). *p<0.05, **p<0.01, ***p<0.001 vs compound alone. 
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In contrast, SB-202190 reduced the rise in IL-1β release caused by addition of extracellular ATP to 
LPS-, zymosan- or poly(I:C)-primed spinal cord microglia (Figure 45), while norephinephrine was 
without effect.  
Figure 45. The p38 MAPK inhibitor SB-202190 reduces the rise in IL-1β release caused by addition of 
extracellular ATP to LPS-, zymosan or poly(I:C) primed spinal cord microglia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Purified neonatal rat spinal cord microglia were seeded in 96 well plates (100,000 cells), and incubated the 
following day with: 10 µM SB-202190 ('SB') or 10 µM norepinephrine ('NE') for 30 minutes, followed by 
addition of: (A) 10 ng/ml LPS, (B) 3 µg/ml zymosan ('Zy'), (C) 50 µg/ml poly(I:C) ('Poly') for 2 h, and then 
5 mM ATP for 1 h. IL-1β content of the culture medium was then determined by ELISA. Data are means ± 
SEM (triplicate culture wells). *p<0.05, ***p<0.001 vs the same conditions without SB-202190. 
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4. DISCUSSION 
Although inflammation is a protective cellular response aimed at removing injurious stimuli and 
initiating the healing process, prolonged inflammation, known as chronic inflammation, goes 
beyond physiological control, and eventually destructive effects override the beneficial effects. 
Nowadays, persistent inflammation is considered as an underlying contributor to virtually every 
chronic disease, including neuropathic pain. Recent studies demonstrate that chronic inflammation 
in the CNS is also a hallmark of various neurodegenerative disorders in which progressive loss of 
structure and function of neurons and neuronal death are observed (Barnum and Tansey, 2010; 
Dauer and Przedborski, 2003; Gao et al., 2003; Giovannini et al., 2002; Jantaratnotai et al., 2003). 
For example, the concentration of nitrite, a metabolite of NO, increases in the cerebrospinal fluid of 
patients with PD and AD in comparison with age-matched controls (Qureshi et al., 1995). 
Consistently, the ablation of iNOS in mutant mice significantly protects dopaminergic neurons from 
MPTP neurotoxicity, indicating that iNOS is essential in MPTP-induced substantia nigra pars 
compacta dopaminergic neurodegeneration (Dehmer et al., 2000). A variety of pro-inflammatory 
cytokines, including TNF-α, IL-1β, IL-6, eicosanoids, and other immune neurotoxins, are found in 
either cerebrospinal fluid or affected brain regions of patients with neurodegenerative disorders 
(Nagatsu et al., 2000). Finally, NF-κB, a transcription factor required for the transcription of most 
proinflammatory molecules, is activated in the substantia nigra pars compacta of PD patients and 
MPTP-intoxicated mice and monkeys, and selective inhibition of NF-κB in mice and monkeys by 
NF-κB essential modifier-binding domain peptides protects dopaminergic neurons from MPTP 
toxicity (Ghosh et al., 2008; Mondal et al., 2012). Therefore, inflammation is an important target 
for neuronal protection in neurodegenerative disorders and neuropathic pain, the latter which 
typically develops when peripheral nerves are damaged due to surgery, bone compression in cancer, 
diabetes or infection.  
Activation of glial cells (microglia and astroglia) has been implicated in the pathogenesis of a 
variety of neurodegenerative diseases, including AD, PD, Creutzfeldt-Jacob disease, HIV-
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associated dementia, stroke, and multiple sclerosis (Dauer and Przedborski, 2003; Ghosh et al., 
2008; González-Scarano and Baltuch, 1999). Glia act also as a link between neuroinflammation and 
neuropathic pain (Jha et al., 2012). Activated microglia and astroglia accumulate at sites of injury or 
plaques in neurodegenerative CNS (González-Scarano and Baltuch, 1999; Carson, 2002). Although 
activated microglia scavenge dead cells from the CNS and secrete different neurotrophic factors for 
neuronal survival and activated astrocytes may have important beneficial effects in the recovery of 
injured CNS by actively monitoring and controlling the extracellular water, pH, and ion 
homeostasis, it is believed that severe activation of these brain cells causes various autoimmune 
responses leading to neuronal death and brain injury (Dauer and Przedborski, 2003; González-
Scarano and Baltuch, 1999; Carson, 2002). During activation, microglia and astroglia express 
various genes related to inflammation, such as proinflammatory cytokines, proinflammatory 
enzymes, and proinflammatory adhesion molecules. Therefore, characterization of signaling 
pathways required for the activation of glial cells is an active area of investigation because 
compounds capable of antagonizing such signaling steps may have therapeutic benefit in 
neurodegenerative disorders and neuropathic pain. 
It is well-known that ATP can serve as an important chemical gliotransmitter that mediates a 
broad range of physiological and pathological processes in the nervous system (Burnstock, 2007). 
ATP acts as a short-term signalling molecule in neurotransmission, neuromodulation and secretion 
and has long-term (trophic) roles in cell proliferation, differentiation and death in development and 
regeneration. Three subclasses of purine and pyrimidine receptors have been identified, P1 
adenosine receptors, P2X ionotropic nucleotide receptors and P2Y metabotropic receptors. ATP is 
released physiologically by many cell types by mechanical deformation and, after release, ATP 
undergoes ectonucleotidase degradation. Purinergic receptors appeared early in evolution and have 
a widespread distribution on many non-neuronal cells and neurons. Purinergic signalling is involved 
in embryonic and stem cell development. There is a rapidly growing literature dealing with the 
pathophysiology of purinergic signalling, including therapeutic developments for diseases both 
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outside (for example, thrombosis, osteoporosis, kidney failure, cystic fibrosis, and cancer) and 
within the nervous system (cerebral ischemia, chronic neurodegenerative disorders, pain) 
(Burnstock, 2011). 
ATP is a key neurotransmitter in the development and maintenance of neuropathic pain 
(Burnstock, 2009; Inoue and Tsuda, 2009; Tsuda et al., 2010). Both P2Y and P2X purinoceptors are 
widely distributed in the sensory nervous system and exhibit various effects both at neuronal and 
glial cells (Burnstock and Knight, 2004; Ruan et al., 2005; Zeng et al., 2009). Microglia are 
activated in response to a diversity of stimuli, ranging from peripheral inflammation to CNS injury, 
which is necessary and sufficient to induce neuropathic pain. There is abundant evidence that 
microglia are activated in the dorsal horn in a wide variety of nerve injury models (Gwak et al., 
2012; Itoh et al., 2011). Following nerve injury, there are many molecular and cellular changes of 
the peripheral and central nervous systems, among which ATP and its purine receptors have been 
widely studied. The signal(s) for activating microglia in these models of neuropathic pain is unclear, 
but it has been proven that microglia are exquisitely responsive to extracellular ATP, which is 
released by cellular damage, nearby astrocytes or neurons from either synaptic or non-synaptic 
regions (Davalos et al., 2005; Di Virgilio, 2006). 
The P2X7R is a unique member of the P2X receptor family, because it is activated only by high 
concentrations of ATP (>100 μM) and its prolonged exposure to ATP has been shown to form a 
much larger pore than any other P2X channel (North, 2002). Numerous studies indicate that P2X7R 
is linked to responses associated to spinal cord damage and inflammation being primary mediators 
of pain sensation (Broom et al., 2008; Chessell et al., 2005; Honore et al., 2006; McGaraughty et 
al., 2006). P2X7R−/− mice do not develop either mechanical allodynia or thermal hyperalgesia in a 
partial nerve ligation model (Chessell et al., 2005). P2X7R is primarily expressed in microglia and 
peripheral macrophages. A recent study has demonstrated that P2X7R is required for the activation 
and proliferation of microglia, suggesting that it regulates immune function and inflammatory 
responses (Monif et al., 2009). Activation of P2X7R can promote the release of some cytokines 
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such as IL-1β and IL-17, as well as superoxide products, all of which play important roles in the 
generation or maintenance of pain. Further, functional P2X7Rs have been demonstrated in 
peripheral glial cells in rat dorsal root ganglion, and this may participate also in peripheral sensory 
transduction of pain perception (Zhang et al., 2005). 
In this study, a LPS-primed, P2X7R-dependent response (IL-1β release) has been characterized 
in purified microglia cultured from rat cortex, spinal cord and cerebellum. While confirming the 
behavior of cortical microglia, this is the first report of a priming response in cells from spinal cord 
and cerebellum. Here, P2X7R dependence was demonstrated by the use of a series of receptor-
selective anagonists of varying potency, which blocked in a cencentration-dependent manner the 
ATP- but not LPS-dependent component of IL-1β release. These same antagonists were initially 
described using cell lines over-expressing the recombinant P2X7R, in terms of calcium flux 
(Donnelly-Roberts and Jarvis, 2007); however, there efficiacy versus priming-dependent IL-1β 
release was not mentioned. These findings are relevant in terms of the importance ascribed to spinal 
cord microglia in neuropathic pain (He et al., 2012). For example, in the dorsal horn of spinal cord, 
pharmacological inhibition of the P2X7R prevents LPS-induced release of IL-1β; cytokine release 
is also absent in spinal cord slices taken from P2X7R knock-out mice (Clark et al., 2010). 
Application of ATP did not evoke release of IL-1β from the dorsal horn unless preceded by an LPS 
priming stimulus, and this release was dependent on P2X7R activation.  Further, activation of 
cerebellar microglia has recently been reported to play a heretofore unknown role in cerebellar 
function, including release of pro-inflammatory cytokines such as IL-1β (Cutando et al., 2012). 
Extensive phosphorylation of p38 MAPK in microglial cells in the dorsal horn was found to 
correlate with IL-1β secretion following both LPS and ATP (Clark et al., 2010). In addition, 
activation of Src family kinases in spinal microglia contributes to formalin-induced persistent pain 
through the p38-MAPK pathway (Tan et al., 2012). In accord with the latter observations, when 
cortical and spinal cord microglia were pretreated for 30 minutes with selective p38 inhibitors (SB-
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202190, SB-239063) IL-1β output from ATP-challenged and LPS-primed spinal cord and cortical 
microglia was reduced. Rather unexpectedly, when SB-202190-treated microglia were incubated 
with LPS for 24 hours IL-1β release was markedly increased over that for LPS alone. Conceivably, 
this could represent a form of positive feedback control, although there is no published evidence for 
such a phenomenon. This effect appeared to be specific for IL-1β release mdiated by long-term LPS 
stimulation of microglia, as the p38 inhibitor did not augment release of either IL-6 or NO (output 
of NO actually decreased). The β-adrenergic receptor agonist noradrenaline concentration-
dependently decreased NO and IL-1β production from 24-hour LPS-stimulated microglia, as 
described by others (Dello Russo et al., 2004), but did not alter the IL-1β release LPS-primed, ATP-
treated cells. The form(s) of IL-1β released (precursor versus mature) under these different 
conditions remains to be deterimed. 
Until now there have been no reports of a P2X7R-dependent priming response in astrocytes. 
Astrocytes are the predominant cell type in the CNS, and such would be an important factor in 
neuroinflammation. Indeed, the first set of experiments described here suggested that astrocytes also 
are able to release IL-1β following addition of extracellular ATP to LPS-primed cells. It is not 
uncommon for astrocyte cultures to be contaminated by microglia (as shown here), and this can 
alter astrocyte responses (Brown et al., 1996; Ciccarelli et al., 2000; Xiong et al., 1999). Pro-
inflammatory stimuli can affect the expression of similar genes in microglia and astrocytes, and 
interpretation of results using astrocyte cultures can be confounded by the presence of 
contaminating microglia (Saura et al., 2003; Solà et al., 2002). To obviate this potential problem, 
the enriched astrocyte cultures were depleted of residual microglia using the lysosomotropic agent 
L-LME.  L-LME accumulates in the lysosomes of lytic cells such as cytotoxic T cells, macrophages 
and microglia, producing membranolytic products of structure (Leu-Leu)n-OMe (n>3) by cathepsin 
C (a lysosomal thiol protease). Molecular biological, immunocytochemical, and biochemical 
methods clearly showed that L-LME-treated astrocytes were dovoid of detectable numbers of 
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microglia. Further, these purified astrocytes (cortical, spinal cord) failed to respond to LPS, in terms 
of mRNA induction and NO and cytokine output. When astrocyte/microglia co-cultures were 
reconstituted by adding defined numbers of microglia to purified astrocytes, LPS responsiveness 
was restored. It is important to note here that LPS sensitivity of the astrocyte/microglia co-cultures 
far exceeded that of equivalent numbers of microglia alone. 
Whether or not microglia are the main producers of the genes/products studied is a key point in 
this study. Factors released from microglia can affect astrocyte responses to LPS (Holm et al., 
2012).  Further, IL-1β can activate astrocytes (Guo et al., 2004) leading, e.g. to increased 
production of NO (Chao et al., 1996). Addition of IL-1β to microglia-depleted astrocytes, up to 
amounts produced by the equivalent of 100,000 microglia in a 96-well culture did not lead to 
release of NO. Analyzing the gene products such as cytokines in these cultures is technically 
difficult, as the cytokines are largely released into the culture medium. At least in the case of NO 
production, this phenomenon did not depend on soluble factors released from LPS-treated 
astrocytes, as conditioned medium from 24-h LPS-treated purified astrocytes failed to induce a 
greater output of NO from microglia than direct LPS addition to the latter. Moreover, a heightened 
responsiveness of the astrocyte/microglia co-cultures was also observed for LPS/ATP priming.     
That mediator output in the microglia/astrocyte co-cultures was far in excess of that found for the 
same numbers of microglia cultured alone suggests that these two glia cell types influence their 
collective response to LPS. These observations may explain, in part, the perceived role of astrocytes 
in pain (Chiang et al., 2012). Astrocytes can produce microglial mitogens (Shafit-Zagardo et al., 
1993); however, these are unlikely to have influenced the astrocyte/microglia co-culture behaviors, 
given the relatively short time span of the experiments. To avoid potential effects of mitogenic 
factors, the co-cultures were not used at longer times. Thus, one cannot determine if prolonged co-
culture incubation time before challenge with LPS would have resulted in even more robust 
responses.  
 112 
 Many studies have shown that P2X7R immunoreactivity is increased in activated microglia of 
many models of diseases, such as AD, multiple sclerosis, amyotrophic lateral sclerosis and focal 
cerebral ischemia (McLarnon et al., 2006; Parvathenani et al., 2003; Yanagisawa et al., 2008; 
Yiangou et al., 2006), while increased expression of P2X7R mRNA has been described in AD-
derived microglia compared to non-demented brain (McLarnon et al., 2006) - suggesting that 
microglial P2X7R might be a general mediator of stress during pathological states. Despite 
unequivocal evidence for Aβ-mediated activation of microglia, the plasma membrane receptors 
involved are largely unknown. Sanz et al. (2009) reported that the Aβ fragment (25-35) triggered 
increases IL-1β secretion in LPS-primed microglia from wild-type but not from P2X7R-deleted 
mice. To examine further the ability of Aβ to trigger IL-1β release from LPS-primed purified 
microglia and enriched astrocytes, these two glial cell populations were first incubated with 1 µg/ml 
LPS for 2 h, followed by addition of either Aβ(25-35) or Aβ(1-42) (20 µM), or 5 mM ATP. Aβ(1-
42) is the peptide that is initially deposited within the extracellular plaques of AD patients and is 
highly prone to aggregation. Soluble oligomers of Aβ(1-42) are now believed to be the principal 
pathological form and are synaptotoxic (Lacor et al., 2007). However, neither Aβ peptide was able 
to mimic the effect of ATP in enhancing IL-1β release from LPS-primed cortical microglia. 
Chronic and acute ethanol intoxication alters brain structure and function, and in some cases can 
lead to neurodegeneration. Concentrations of ethanol found in drinkers (10 mM) promote 
inflammatory processes in brain and in glial cells by up-regulating cytokines and inflammatory 
mediators (iNOS, NO, COX-2) and transcription factors implicated in inflammatory injury (Blanco 
and Guerri, 2007). Pharmacological block or genetic deletion of TLRs abolishes the production of 
ethanol-induced inflammatory mediators and cell death (Blanco and Guerri, 2007; Fernandez-
Lizarbe et al., 2009). However, 10-100 mM ethanol failed to provoke production of NO from spinal 
cord and cortical microglia – unlike LPS. When cortical and spinal cord microglia were incubated 
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with 100 mM ethanol or 1 µg/ml LPS for 2 h, followed by challenge with 5 mM ATP for 1 h, IL-1β 
was released into the culture medium with LPS, while ATP was ineffective in ethanol 'primed' cells.  
Here we show for the first time that agonists for TLR2 (zymosan) or TLR3 (poly(I:C)) are also 
capable of priming microglia for ATP-dependent IL-1β release. As with LPS, the p38 MAPK 
inhibitor SB-202190 reduced the rise in IL-1β release caused by addition of extracellular ATP to 
zymosan or poly(I:C) primed microglia, while norephinephrine was without effect. In contrast, but 
in keeping with the data for microglia subjected to a 24-h incubation with LPS, SB-202190 
markedly raised IL-1β release from cells incubated with zymosan and poly(I:C) for 24 h, while 
norepinephrine reduced IL-1β release. These findings broaden considerably the potential role of 
P2X7R in inflammation-associated neuropathologies, and support the idea that a better 
understanding of astrocyte/microglia interactions may improve our understanding in how these cells 
respond to CNS injury or inflammation, in particular where TLRs are involved. 
Increasing emphasis is now being placed on TLR signaling pathways in neurodegenerative 
disorders (Campbell, 2004; Jin et al., 2008; Okun et al., 2009), including motor neuron disease (Liu 
et al., 2009; Casula et al., 2011), brain injury (Campbell, 2004) and neuropathic pain (Christianson 
et al., 2011). Systemic bacterial insults accelerate disease progression in animals and in patients 
with AD (Cunnungham et al., 2005). There are reports of exacerbation of chronic CNS pathology 
by systemic gram-negative bacterial stimulation in a model of prion disease and in animal models 
of PD (Godoy et al., 2008), amyotrophic lateral sclerosis (Nguyen et al., 2004), AD (Sly et al., 
2001) and ageing (Godbout et al., 2005). In addition to exogenous microbial products like LPS, 
endogenous products can activate TLRs during sterile inflammation. Besides TLR4, microglia also 
express functional TLR2 (Kim et al., 2007; Shi et al., 2011) and TLR3 (Obata et al., 2008; Mei et 
al., 2011) proteins, whose activation participates in nerve injury-induced neuropathic pain. A recent 
report also demonstrated that systemic challenge with the TLR3 agonist poly(I:C) induces amplified 
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IFNα/β and IL-1β responses in the diseased brain and exacerbates chronic neurodegeneration (Field 
et al., 2010). 
 
Epilogue 
It is now generally accepted that high levels of extracellular nucleotides such as ATP may be 
released under pathological conditions such as inflammation, trauma, and stress. Recent findings 
suggest that increased P2X7R numbers drive microglial activation, rather than P2X7R over-
expression being a consequence of microglial activation (Monif et al., 2009). Signaling via P2X7Rs 
may thus allow cells to sense and respond to events occurring in the extracellular environment, 
modulate the transcription of genes involved in cellular inflammatory processes and to thus regulate 
cytokine responses. The therapeutic exploitation of P2X7Rs is now under way because of their 
potential role, not only in such disorders as AD, spinal cord injury, and sensory neuropathies but 
also in multiple sclerosis, neuropathic pain, and rheumatoid arthritis, (Broom et al., 2008; 
Romagnoli et al., 2008; Volonté et al., 2012) as well as depressive illness. There is growing 
appreciation for the role of P2X7R modulation of pro-inflammatory IL-1β processing, and the 
analgesic activity of P2X7R antagonists. At the same time, recent findings (Chen et al., 2008) 
suggest that alternative therapeutic strategies for controlling pain may be to target P2X7R-
associated proteins such as PanX1 hemichannels, which are directly involved in the damaging 
effects of P2X7R activation (Pelegrin and Surprenant, 2006). P2X7Rs are expressed with some 
selectivity on different types of cells in the cardiovascular system, and drugs affecting P2X7R 
signaling may have promise as antihypertensive and anti-thrombotic agents (Ralevic and Burnstock, 
2003). Further investigation of the P2X7R with receptor sub-selective antagonists in preclinical 
studies as well as in disease-specific clinical trials will be critical to evaluating this target’s potential 
therapeutic use. 
Looking beyond the data presented here, it would be of interest to investigate a role for P2X7R 
in glia-mediated injury to dopaminergic neurons. Glia/neuron co-cultures can be prepared from the 
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mesencephalic area, which contain a minor population of dopaminergic neurons. Subjecting such 
cultures to LPS as an inflammatory stimulus has been reported to result in the selective loss of 
dopaminergic neurons (Peng et al., 2005), which is microglia-mediated. Using the experience 
developed here, it should be possible to selective manipulate the glial cell contribution in such 
cultures. Another line of investigation worth pursuing would be that of looking at the potential for 
one TLR to regulate expression of others, for example, would a TLR4 agonist influence TLR2 
and/or TLR3 expression, and vice versa. This could be extended also to examine whether or not 
TLR activation can influence expression of nuclear receptors, whose activation is known to have 
anti-inflammatory actions. Finally, preliminary experiments indicate that the observed 
astrocyte/microglia co-culture behaviors with LPS occur also when using agents which activate 
TLR2 and TLR3. Future experiments may explore both the generally of this astrocyte-microglia 
interaction, utilizing astrocyte/microglia co-cultures and other TLR agonists, in terms of long-term 
activation and the ATP priming response. In the latter case, mediator release assessment could be 
extended to include, besides IL-1β, also IL-18 (released as the mature polypeptide following 
P2X7R activation) which contributes to neuroinflammation and neuropathic pain following 
peripheral nerve injury in mice (Kim Kim and Moalem-Taylor, 2011). 
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